

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :		A1	(11) International Publication Number: WO 98/28425
C12N 15/19, C07K 14/54, C12N 15/62, G01N 33/50, C12Q 1/68, A61K 38/19, C12N 5/10, A01K 67/00			(43) International Publication Date: 2 July 1998 (02.07.98)
(21) International Application Number: PCT/US97/22975		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 22 December 1997 (22.12.97)			
(30) Priority Data: 60/034,151 23 December 1996 (23.12.96) US 60/042,222 15 April 1997 (15.04.97) US			
(71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033 (US).			
(72) Inventors: BAZAN, J., Fernando; 775 University Drive, Menlo Park, CA 94025 (US). KASTELEIN, Robert, A.; 463 Summit Drive, Redwood City, CA 94062 (US). DE WAAL MALEFYT, Rene; 891 Muender Avenue, Sunnyvale, CA 94040 (US).			
(74) Agents: FOULKE, Cynthia, L. et al.; Schering-Plough Corporation, Patent Dept. K-6-1, 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).			
<p><b>(54) Title:</b> MAMMALIAN CYTOKINE RELATED TO IL10</p> <p><b>(57) Abstract</b></p> <p>Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## MAMMALIAN CYTOKINE RELATED TO IL10

## FIELD OF THE INVENTION

The present invention pertains to compositions related  
10 to proteins which function in controlling biology and  
physiology of mammalian cells, e.g., cells of a mammalian  
immune system. In particular, it provides purified genes,  
proteins, antibodies, and related reagents useful, e.g., to  
regulate activation, development, differentiation, and  
15 function of various cell types, including hematopoietic  
cells.

## BACKGROUND OF THE INVENTION

Recombinant DNA technology refers generally to the  
20 technique of integrating genetic information from a donor  
source into vectors for subsequent processing, such as  
through introduction into a host, whereby the transferred  
genetic information is copied and/or expressed in the new  
environment. Commonly, the genetic information exists in  
25 the form of complementary DNA (cDNA) derived from messenger  
RNA (mRNA) coding for a desired protein product. The  
carrier is frequently a plasmid having the capacity to  
incorporate cDNA for later replication in a host and, in  
some cases, actually to control expression of the cDNA and  
30 thereby direct synthesis of the encoded product in the host.

For some time, it has been known that the mammalian  
immune response is based on a series of complex cellular  
interactions, called the "immune network". Recent research  
has provided new insights into the inner workings of this  
35 network. While it remains clear that much of the response  
does, in fact, revolve around the network-like interactions

of lymphocytes, macrophages, granulocytes, and other cells, immunologists now generally hold the opinion that soluble proteins, known as lymphokines, cytokines, or monokines, play a critical role in controlling these cellular interactions. Thus, there is considerable interest in the isolation, characterization, and mechanisms of action of cell modulatory factors, an understanding of which will lead to significant advancements in the diagnosis and therapy of numerous medical abnormalities, e.g., immune system disorders.

Lymphokines apparently mediate cellular activities in a variety of ways. They have been shown to support the proliferation, growth, and differentiation of pluripotential hematopoietic stem cells into vast numbers of progenitors comprising diverse cellular lineages making up a complex immune system. Proper and balanced interactions between the cellular components are necessary for a healthy immune response. The different cellular lineages often respond in a different manner when lymphokines are administered in conjunction with other agents.

Cell lineages especially important to the immune response include two classes of lymphocytes: B-cells, which can produce and secrete immunoglobulins (proteins with the capability of recognizing and binding to foreign matter to effect its removal), and T-cells of various subsets that secrete lymphokines and induce or suppress the B-cells and various other cells (including other T-cells) making up the immune network. These lymphocytes interact with many other cell types.

Another important cell lineage is the mast cell (which has not been positively identified in all mammalian species), which is a granule-containing connective tissue cell located proximal to capillaries throughout the body. These cells are found in especially high concentrations in the lungs, skin, and gastrointestinal and genitourinary tracts. Mast cells play a central role in allergy-related

disorders, particularly anaphylaxis as follows: when selected antigens crosslink one class of immunoglobulins bound to receptors on the mast cell surface, the mast cell degranulates and releases mediators, e.g., histamine, 5 serotonin, heparin, and prostaglandins, which cause allergic reactions, e.g., anaphylaxis.

Research to better understand and treat various immune disorders has been hampered by the general inability to maintain cells of the immune system in vitro. Immunologists 10 have discovered that culturing these cells can be accomplished through the use of T-cell and other cell supernatants, which contain various growth factors, including many of the lymphokines.

The gene encoding IL-10, originally designated Cytokine 15 Synthesis Inhibitory Factor (CSIF), was isolated in the 1980's. See, e.g., Mosmann, et al., U.S. Patent No. 5,231,012. Since then, much has been learned of the biology and physiology mediated by the cytokine. See, e.g., de Vries and de Waal Malefyt (1995) Interleukin-10 Landes Co., 20 Austin, TX.

From the foregoing, it is evident that the discovery and development of new lymphokines, e.g., related to IL-10, could contribute to new therapies for a wide range of degenerative or abnormal conditions which directly or 25 indirectly involve the immune system and/or hematopoietic cells. In particular, the discovery and development of lymphokines which enhance or potentiate the beneficial activities of known lymphokines would be highly advantageous. The present invention provides new 30 interleukin compositions and related compounds, and methods for their use.

#### SUMMARY OF THE INVENTION

The present invention is directed to mammalian, e.g., 35 rodent, canine, feline, primate, interleukin-BKW (IL-BKW), and its biological activities. It includes nucleic acids

coding for polypeptides themselves and methods for their production and use. The nucleic acids of the invention are characterized, in part, by their homology to cloned complementary DNA (cDNA) sequences enclosed herein, and/or 5 by functional assays for IL-10-like activities applied to the polypeptides, which are typically encoded by these nucleic acids. Methods for modulating or intervening in the control of an immune response are provided.

The present invention is based, in part, upon the 10 discovery of a new cytokine sequence exhibiting high sequence and structural similarity to cellular IL-10. In particular, it provides a gene encoding a protein whose mature size is about 158 amino acids. Functional equivalents exhibiting significant sequence homology will be 15 available from other mammalian, e.g., mouse and rat, and non-mammalian species.

In one embodiment, the invention provides a substantially pure or recombinant soluble IL-BKW, including an antigenic protein or peptide fragment of the soluble IL-20 BKW. Preferably, the IL-BKW is a full length natural soluble protein from a mammal, including a primate, or may be in a sterile composition. Typically, the soluble IL-BKW lacks the sequence MNFQQRLQSL WTLARPFCPP LLATASQMQM VVLPCLGFTL LLWSQVSG of SEQ ID NO: 2; is a mature polypeptide 25 of SEQ ID NO: 6; or is encoded by a nucleic acid of SEQ ID NO: 5. Alternatively, the soluble IL-BKW is a full length secreted protein which exhibits a post-translational modification pattern distinct from natural soluble IL-BKW.

Functionally, the soluble IL-BKW will typically exhibit 30 an immunological activity functionally antagonistic to IL-10.

The invention also provides a fusion protein comprising sequence of a soluble IL-BKW, but lacking sequence of MNFQQRLQSL WTLARPFCPP LLATASQMQM VVLPCLGFTL LLWSQVSG of SEQ 35 ID NO: 2; is a mature polypeptide of SEQ ID NO: 6; or is encoded by SEQ ID NO: 5.

The invention also provides a method of purifying a soluble IL-BKW protein or peptide from other materials in a mixture comprising contacting said mixture to an antibody to said protein, and separating bound IL-BKW from other  
5 materials.

In other embodiments, the invention provides an isolated or recombinant expression vector encoding a soluble IL-BKW. Preferably, the vector encodes a secreted sequence of SEQ ID NO: 2 or 6 and may comprise sequence of SEQ ID NO:  
10 1 or 5.

The invention provides a kit for detection comprising a positive control which is a substantially pure soluble IL-BKW or fragment. The kit also provides a method for detecting in a sample for the presence of a soluble IL-BKW  
15 protein, or antibody, comprising testing said sample with the kit.

The invention also provides a method of modulating the physiology of a cell comprising contacting the cell with a substantially pure soluble IL-BKW. In certain embodiments,  
20 the cell is a T cell and the modulating of physiology is inactivation of the T cell; or the cell is in a tissue.

The invention also provides a method of making a soluble IL-BKW comprising expressing a vector. The vector may be in a cell, tissue, or organ.

Finally, the invention provides a method of treating an animal having an abnormal immune response by administering to the animal an effective dose of a substantially pure soluble IL-BKW.  
25

30 BRIEF DESCRIPTION OF THE DRAWING

Figure 1 shows alignment of IL-10 and related cytokines.

## DETAILED DESCRIPTION OF THE INVENTION

All references cited herein are incorporated herein by reference to the same extent as if each individual publication or patent application was specifically and 5 individually indicated to be incorporated by reference.

## I. General

The present invention provides amino acid sequences and DNA sequences encoding various mammalian proteins which are cytokines, e.g., which are secreted molecules which can 10 mediate a signal between immune or other cells. See, e.g., Paul (1994) Fundamental Immunology, Raven Press, N.Y. . The full length cytokines, and fragments, or antagonists will be useful in physiological modulation of cells expressing a receptor. Early data suggests that the cytokine functions 15 to effect the opposite effects that IL-10 does. It is likely that IL-BKW has either stimulatory or inhibitory effects on T-cells, B-cells, natural killer (NK) cells, macrophages, dendritic cells, hematopoietic progenitors, etc. The proteins will also be useful as antigens, e.g., 20 immunogens, for raising antibodies to various epitopes on the protein, both linear and conformational epitopes.

A cDNA encoding IL-BKW was isolated from a human melanoma cell line. The molecule was designated mda7, and was characterized as a novel melanoma differentiation 25 associated gene. SEQ ID NO: 1 and 2. See Jiang, et al. (1995) Oncogene 11:2477-86; Genbank accession number U16261. That paper reported some small homology of the mda7 to human IL-10, but the relevance was unknown. Applicants have analyzed the sequence and believe that the coding region had 30 been misidentified, a fact consistent with the sequence of the mouse gene.

The CDS was proposed by Jiang, et al. to run about from 275..895 to encode:

35 MNFQQRLQSL WTLARPFCPP LLATASQMOM VVLPCLGFTL LLWSQVSGAQ GQEFHFGPCQ  
VKGVVPQKLG EAFWAVKDTM QAQDNITSAR LLQQEVLQNV SDAESCYLVH TLLEFYLKTV  
FKNYHNRTVE VRFLKSFSSTL ANNFVLIVSQ LQPSQELEMF SIRDSAHRRF LLFRRRAFKQL  
DVEAALTAKAL GEVDILLTWM QKFYKL (SEQ ID NO: 2);

however, Applicants propose a mature form of IL-BKW which begins at about the 49th residue, or:

AQGQEFHFGP CQVKGVVPQK LWEAFWAVKD TMQAQDNITS ARLLQQEVLQ NVSDAESCYL  
 VHTLLEFYLK TVFKNYHNRT VEVRTLKSFS TLANNFVLIV SQLQPSQENE MFSIRDSAHR  
 5 RFLLFRRAFK QLDVEAALTK ALGEVDILLT WMQKFYKL.

In Table 1 various human IL-10 embodiments are compared to human IL-BKW.

10

TABLE 1

	IL-BKW	.MQMVVLPCL GFTLLLWSQV SGAQGQEFHF GPCQVK.GVV PQKL...WEA
	IL-10	MHSSALLCCL ..VLLTGVR A SPGQGTQSEN SCTHFP.GNL PNMLRDLRDA
	IL-XX	MLVNIFILRCG ..LLVTLSL AIAHKHQSSF TKSCYPRGTL SQAVDALYIK
15	IL-BKW	FWAVKDTMQA QDNITSAR.L LQQEVQLQNWS DAESCYLVHT LLEFYLKTVF
	IL-10	FSRVKTFQFQM KDQLDNL..L LKESLLEDFFK GYLGCQALSE MIQFYLEEVFM
	IL-XX	AAWLKATIP. EDRIKNIR.L LKKKTKKQFM K..NCOFQEQL LSFFNEDVF
20	IL-BKW	KNYHNRTVEV RTLKSFS TLA NNFVLIVSQL QPSQENEMFS IRDSAHRRFL
	IL-10	PQAENQDPDI ..KAHVNSLG ENLKTTLRLRL RRCHR...FL PCENKS KAVE
	IL-XX	GQLQLQG... .CKKIRFV EDFHTLRQKL SHCIS...CA SSAREMKSIT
	IL-BKW	LFRRRAFKQLD VEAALT KALG EV DILLTWMQ KFYKL....
	IL-10	QVKNAFNKLQ .EKGIYKAMS EFDIFINYIE AYMTMKIRN
25	IL-XX	RMKRIFYRIG .NKGIYKAIS ELDILLSWI K LLESSQ..
	<b>hIL-BKW (SEQ ID NO: 2)</b>	
	<b>hIL-10 (SEQ ID NO: 3)</b>	
	<b>hIL-XX (SEQ ID NO: 4)</b>	
30	See Knappe, et al., USSN 08/718,753.	

A murine clone for IL-BKW (mIL-BKW) has also been isolated from an activated mouse thymocyte cDNA library (A. Zlotnik, DNAX Res. Institute, Palo Alto, CA). SEQ ID NO: 5 and 6. The signal sequence runs from about Met1 to Gly23. The mature polypeptide begins at about Leu24. The conserved D-helix, implicated in receptor binding, runs from about Glu158 to Leu181. There is no corresponding ATG upstream of the leader sequence as found in the human, possibly indicating that this molecule is membrane bound.

mIL-BKW possess a high degree of amino acid sequence identity to the human counterpart. An alignment between hIL-10, mIL-10, hIL-BKW, and mIL-BKW reveals that the D-helix is highly conserved. See Table 2 and SEQ ID NO: 2, 3, 45 6, and 7.

Table 2 compares human and mouse IL-10 and human and mouse IL-BKW. In IL-10, this helix seems particularly important in receptor binding. Therefore, IL-BKW and IL-10 may share the same receptor subunit.

5

TABLE 2

	hIL10	..MHSSALLC C.LVLLTGVR AS..PGQGTQ SENSCTHFPG NLPNMLRDLR
	mIL10	..MPGSALLC C.LLLL TGMR IS..RGQYSR EDNNCTHFPV GQSHMLLELR
	hILBKW	..MQMVVLPC LGFTLLLWSQ VSGAQGQEFH F.GPCQVKGV ....VPQKLW
10	mILBKW	MSWGLQILPC LSLILLLWNQ VPGLLEGQEFR S.GSCQVTGV ....VLPELW
	hIL10	DAFSRVKTFF QMKDQLDNL. LLKESLLED F KGYLG CQALS EMIQFYLEEV
	mIL10	TAFSQVKTFF QTKDQLDNI. LLTDLSLMQDF KGYLG CQALS EMIQFYLV
	hILBKW	EAFWAVKDTM QAQDNITSAR LLQQEVLQNV SDAESCYLVH TLLEFYLKTV
15	mILBKW	EAFWTVKNTV QTQDDITSI R LLKPQVLRNV SGAESCYLAH SLLKFYLN
	hIL10	MPQAENQDPD IK..AHVNSL GENLKTLRLR LRR...CHRF LPCENKSKAV
	mIL10	MPQAEKHGPE IK..EHLNSL GEKLKTLRMR LRR...CHRF LPCENKSKAV
	hILBKW	FKNYHNRTVE VRTLKSFSTL ANNFVLIVSQ LQPSQENEMF SIRDSAHRRF
20	mILBKW	FKNYHSKIAK FKVLRSFSTL ANNFIVIMSQ LQPSKD NSML PISESAHQRF
	hIL10	EQVKNAFNKL Q. EKG IYKAM SEFDIFINYI EAYMTMKIR N
	mIL10	EQVKSDFNKL Q. DQGVYKAM NEFDIFINCI EAYMMIKMK S
	hILBKW	LLFRRRAFKQL DV EAALT KAL GEVDILLTWM QKFYKL...
25	mILBKW	LLFRRRAFKQL DT EVALVKAF GEVDILLTWM QKFYHL...
		<u>D-helix</u>
	hIL-10 (SEQ ID NO: 3)	
	mIL-10 (SEQ ID NO: 7)	
	hIL-BKW (SEQ ID NO: 2)	
30	mIL-BKW (SEQ ID NO: 6).	

Chromosomal mapping using mIL-BKW as a probe revealed that this cytokine maps to the central region of mouse chromosome 1 in between the regions of homology for human chromosomes 2q and 1q. Interestingly, mIL-BKW is located directly adjacent to the gene for mIL-10. Defects in this particular locus have been implicated in immune disorders, e.g., dominant hemimelia. See, e.g., Carter (1954) Mouse News Lett. 11:16; Higgins, et al. (1992) Genet. Res. 60:53-60; and Machado, et al. (1976) Am. J. Pathol. 85:515-518.

The protein had been characterized as an antigen with a predicted hydrophobic stretch encompassing residues 25-45 of the protein. But experiments failed to confirm that a membrane form exists. Applicants believe that the predicted hydrophobic stretch is actually a signal sequence which is removed from the mature protein, which is likely to start at

either residue 47 (Ser) or 49 (Ala), as designated in the original publication.

Applicants believe that the gene encodes a small soluble cytokine-like protein, of about 158 amino acids.

5 The pre-sequence probably starts at either the M at position 28 or 30, thus providing an N-terminal signal sequence of about 17-21 amino acids. See Table 1 and SEQ. ID. NO: 1 and 2. IL-BKW exhibits structural motifs characteristic of a member of the short chain cytokines. Compare, e.g., IL-BKW, 10 cellular IL-10s from mouse and human, EBV viral IL-10, and the Equine herpesvirus IL-10, all sequences available from GenBank. See Table 1.

The structural homology of IL-BKW to the related IL-10 proteins suggests related function of this molecule. IL-BKW 15 is a small chain cytokine. Early experiments suggest that the new cytokine likely mediates immune functions via a receptor of the class of cytokine receptors, though it seems not to share all parts of a functional IL-10 receptor complex.

20 IL-BKW agonists, or antagonists, may also act as functional or receptor antagonists, e.g., which block IL-10 binding to its receptor, or mediating the opposite actions. Thus, IL-BKW, or its antagonists, may be useful in the treatment of abnormal immune disorders, e.g., T cell immune 25 deficiencies, chronic inflammation, or tissue rejection.

The natural antigens are capable of mediating various biochemical responses which lead to biological or physiological responses in target cells. The embodiments characterized herein are from human and mouse, but other 30 primate, or other species counterparts are expected to exist in nature. Additional sequences for proteins in other mammalian species, e.g., primates, canines, felines, and rodents, should also be available. See below. The descriptions below are directed, for exemplary purposes, to 35 a human IL-BKW, but are likewise applicable to related embodiments from other species.

The human and mouse IL-BKW proteins exhibit structural features characteristic of short chain cytokines.

II. Purified IL-BKW

Human IL-BKW amino acid sequence, lacking the N-terminal sequence, e.g., MNFQQRLQSL WTLARPFCPP LLATASQMOM VVLPCLGFTL LLWSQVSG, is shown as one embodiment within SEQ ID NO: 2. The corresponding mIL-BKW amino acid sequence is shown in SEQ ID NO: 6. These amino acid sequences, provided amino to carboxy, are important in providing sequence information in the cytokine allowing for distinguishing the protein antigen from other proteins and exemplifying numerous variants. Moreover, the peptide sequences allow preparation of peptides to generate antibodies to recognize such segments, and nucleotide sequences allow preparation of oligonucleotide probes, both of which are strategies for detection or isolation, e.g., cloning, of genes encoding such sequences. Potential glycosylation sites on the human sequence are asn31-thr39 and asn51-ser53; and on the mouse asn51-ser53.

As used herein, the term "human soluble IL-BKW" shall encompass, when used in a protein context, a protein having amino acid sequence corresponding to a soluble polypeptide shown in SEQ ID NO: 2, e.g., lacking the amino terminal portion described as membrane associated (MNFQQRLQSL WTLARPFCPP LLATASQMOM VVLPCLGFTL LLWSQVSG). Such will lack the first 45 residues described as the N terminus by Jiang, et al., or significant fragments thereof. "Mouse IL-BKW" shall encompass the amino acid sequence corresponding to SEQ ID NO: 6. Binding components, e.g., antibodies, typically bind to an IL-BKW with high affinity, e.g., at least about 100 nM, usually better than about 30 nM, preferably better than about 10 nM, and more preferably at better than about 3 nM. Homologous proteins would be found in mammalian species other than human, e.g., other primates or rodents. Non-mammalian species should also possess structurally or

functionally related genes and proteins, e.g., birds or amphibians.

The term "polypeptide" as used herein includes a significant fragment or segment, and encompasses a stretch 5 of amino acid residues of at least about 8 amino acids, generally at least about 12 amino acids, typically at least about 16 amino acids, preferably at least about 20 amino acids, and, in particularly preferred embodiments, at least about 30 or more amino acids, e.g., 35, 40, 45, 50, etc.

10 Such fragments may have ends which begin and/or end at virtually all positions, e.g., beginning at residues 1, 2, 3, etc., and ending at, e.g., 150, 149, 148, etc., in all combinations. Particularly interesting peptides have ends corresponding to structural domain boundaries, e.g., helices 15 A, B, C, and/or D. See Table 1, Table 2, and Figure 1. Note that the sequence of IL-BKW exhibits particular identity to cellular IL-10 in the region from residue 126-137, and the other regions exhibit greater extents of IL-BKW specific sequence.

20 The term "binding composition" refers to molecules that bind with specificity to IL-BKW, e.g., in an antibody-antigen interaction. It also includes compounds, e.g., proteins, which specifically associate with IL-BKW, including in a natural physiologically relevant protein-protein interaction, either covalent or non-covalent. The 25 molecule may be a polymer, or chemical reagent. A functional analog may be a protein with structural modifications, or it may be a molecule which has a molecular shape which interacts with the appropriate binding determinants. The compounds may serve as agonists or 30 antagonists of a receptor binding interaction, see, e.g., Goodman, et al. (eds.) (1990) Goodman & Gilman's: The Pharmacological Bases of Therapeutics (8th ed.), Pergamon Press.

35 Substantially pure typically means that the protein is free from other contaminating proteins, nucleic acids, or

other biologicals derived from the original source organism. Purity may be assayed by standard methods, typically by weight, and will ordinarily be at least about 40% pure, generally at least about 50% pure, often at least about 60% 5 pure, typically at least about 80% pure, preferably at least about 90% pure, and in most preferred embodiments, at least about 95% pure. Carriers or excipients will often be added.

Solubility of a polypeptide or fragment depends upon the environment and the polypeptide. Many parameters affect 10 polypeptide solubility, including temperature, electrolyte environment, size and molecular characteristics of the polypeptide, and nature of the solvent. Typically, the temperature at which the polypeptide is used ranges from about 4° C to about 65° C. Usually the temperature at use 15 is greater than about 18° C. For diagnostic purposes, the temperature will usually be about room temperature or warmer, but less than the denaturation temperature of components in the assay. For therapeutic purposes, the temperature will usually be body temperature, typically 20 about 37° C for humans and mice, though under certain situations the temperature may be raised or lowered in situ or in vitro.

The size and structure of the polypeptide should generally be in a substantially stable state, and usually 25 not in a denatured state. The polypeptide may be associated with other polypeptides in a quaternary structure, e.g., to confer solubility, or associated with lipids or detergents.

The solvent and electrolytes will usually be a biologically compatible buffer, of a type used for 30 preservation of biological activities, and will usually approximate a physiological aqueous solvent. Usually the solvent will have a neutral pH, typically between about 5 and 10, and preferably about 7.5. On some occasions, one or more detergents will be added, typically a mild non- 35 denaturing one, e.g., CHS (cholesteryl hemisuccinate) or CHAPS (3-[3-cholamidopropyl]dimethylammonio)-1-propane

sulfonate), or a low enough concentration as to avoid significant disruption of structural or physiological properties of the protein.

### III. Physical Variants

5 This invention also encompasses proteins or peptides having substantial amino acid sequence identity with the amino acid sequence of the IL-BKW antigen. The variants include species, polymorphic, or allelic variants.

Amino acid sequence homology, or sequence identity, is  
10 determined by optimizing residue matches, if necessary, by introducing gaps as required. See also Needleham, et al.  
(1970) J. Mol. Biol. 48:443-453; Sankoff, et al. (1983)

Chapter One in Time Warps, String Edits, and Macromolecules: The Theory and Practice of Sequence Comparison, Addison-

15 Wesley, Reading, MA; and software packages from IntelliGenetics, Mountain View, CA; and the University of Wisconsin Genetics Computer Group, Madison, WI. Sequence identity changes when considering conservative substitutions as matches. Conservative substitutions typically include

20 substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. The conservation may apply to biological features, functional

25 features, or structural features. Homologous amino acid sequences are typically intended to include natural polymorphic or allelic and interspecies variations in each respective protein sequence. Typical homologous proteins or peptides will have from 25-100% identity (if gaps can be

30 introduced), to 50-100% identity (if conservative substitutions are included) with the amino acid sequence of the IL-BKW. Identity measures will be at least about 35%, generally at least about 40%, often at least about 50%, typically at least about 60%, usually at least about 70%,

35 preferably at least about 80%, and more preferably at least about 90%.

The isolated IL-BKW DNA can be readily modified by nucleotide substitutions, nucleotide deletions, nucleotide insertions, and inversions of nucleotide stretches. These modifications result in novel DNA sequences which encode 5 these antigens, their derivatives, or proteins having similar physiological, immunogenic, antigenic, or other functional activity. These modified sequences can be used to produce mutant antigens or to enhance expression. Enhanced expression may involve gene amplification, 10 increased transcription, increased translation, and other mechanisms. "Mutant IL-BKW" encompasses a polypeptide otherwise falling within the sequence identity definition of the IL-BKW as set forth above, but having an amino acid sequence which differs from that of IL-BKW as normally found 15 in nature, whether by way of deletion, substitution, or insertion. This generally includes proteins having significant identity with a protein having sequence of SEQ ID NO: 2 or 6, and as sharing various biological activities, e.g., antigenic or immunogenic, with those sequences, and in 20 preferred embodiments contain most of the full length disclosed sequences. Full length sequences will typically be preferred, though truncated versions will also be useful, likewise, genes or proteins found from natural sources are typically most desired. Similar concepts apply to different 25 IL-BKW proteins, particularly those found in various warm blooded animals, e.g., mammals and birds. These descriptions are generally meant to encompass all IL-BKW proteins, not limited to the particular mouse embodiments specifically discussed.

30 IL-BKW mutagenesis can also be conducted by making amino acid insertions or deletions. Substitutions, deletions, insertions, or any combinations may be generated to arrive at a final construct. Insertions include amino- or carboxy-terminal fusions. Random mutagenesis can be 35 conducted at a target codon and the expressed mutants can then be screened for the desired activity. Methods for

making substitution mutations at predetermined sites in DNA having a known sequence are well known in the art, e.g., by M13 primer mutagenesis or polymerase chain reaction (PCR) techniques. See, e.g., Sambrook, et al. (1989); Ausubel, et al. (1987 and Supplements); and Kunkel, et al. (1987) Methods in Enzymol. 154:367-382.

The present invention also provides recombinant proteins, e.g., heterologous fusion proteins using segments from these proteins. A heterologous fusion protein is a fusion of proteins or segments which are naturally not normally fused in the same manner. A similar concept applies to heterologous nucleic acid sequences.

In addition, new constructs may be made from combining similar functional domains from other proteins. For example, target-binding or other segments may be "swapped" between different new fusion polypeptides or fragments. See, e.g., Cunningham, et al. (1989) Science 243:1330-1336; and O'Dowd, et al. (1988) J. Biol. Chem. 263:15985-15992.

The phosphoramidite method described by Beaucage and Carruthers (1981) Tetra. Letts. 22:1859-1862, will produce suitable synthetic DNA fragments. A double stranded fragment will often be obtained either by synthesizing the complementary strand and annealing the strand together under appropriate conditions or by adding the complementary strand using DNA polymerase with an appropriate primer sequence, e.g., PCR techniques.

#### IV. Functional Variants

The blocking of physiological response to IL-BKWs may result from the competitive inhibition of binding of the ligand to its receptor. Preliminary results suggest that the IL-BKW does not bind to the same as the described subunit of the receptor for IL-10. An IL-BKW antagonist would be expected to have the opposite effect as IL-BKW.

In vitro assays of the present invention will often use isolated protein, soluble fragments comprising receptor binding segments of these proteins, or fragments attached to

solid phase substrates. These assays will also allow for the diagnostic determination of the effects of either binding segment mutations and modifications, or cytokine mutations and modifications, e.g., IL-BKW analogs.

5 This invention also contemplates the use of competitive drug screening assays, e.g., where neutralizing antibodies to the cytokine, or receptor binding fragments compete with a test compound.

10 "Derivatives" of IL-BKW antigens include amino acid sequence mutants from naturally occurring forms, glycosylation variants, and covalent or aggregate conjugates with other chemical moieties. Covalent derivatives can be prepared by linkage of functionalities to groups which are found in IL-BKW amino acid side chains or at the N- or C-15 termini, e.g., by standard means. See, e.g., Lundblad and Noyes (1988) Chemical Reagents for Protein Modification, vols. 1-2, CRC Press, Inc., Boca Raton, FL; Hugli (ed.) (1989) Techniques in Protein Chemistry, Academic Press, San Diego, CA; and Wong (1991) Chemistry of Protein Conjugation 20 and Cross Linking, CRC Press, Boca Raton, FL.

In particular, glycosylation alterations are included, e.g., made by modifying the glycosylation patterns of a polypeptide during its synthesis and processing, or in further processing steps. See, e.g., Elbein (1987) Ann. 25 Rev. Biochem. 56:497-534. Also embraced are versions of the peptides with the same primary amino acid sequence which have other minor modifications, including phosphorylated amino acid residues, e.g., phosphotyrosine, phosphoserine, or phosphothreonine.

30 Fusion polypeptides between IL-BKWs and other homologous or heterologous proteins are also provided. Many cytokine receptors or other surface proteins are multimeric, e.g., homodimeric entities, and a repeat construct may have various advantages, including lessened susceptibility to 35 proteolytic cleavage. Typical examples are fusions of a reporter polypeptide, e.g., luciferase, with a segment or

domain of a protein, e.g., a receptor-binding segment, so that the presence or location of the fused ligand may be easily determined. See, e.g., Dull, et al., U.S. Patent No. 4,859,609. Other gene fusion partners include bacterial  $\beta$ -galactosidase, trpE, Protein A,  $\beta$ -lactamase, alpha amylase, alcohol dehydrogenase, yeast alpha mating factor, and detection or purification tags such as a FLAG sequence of His6 sequence. See, e.g., Godowski, et al. (1988) Science 241:812-816.

10        Fusion peptides will typically be made by either recombinant nucleic acid methods or by synthetic polypeptide methods. Techniques for nucleic acid manipulation and expression are described generally, e.g., in Sambrook, et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed.), 15 vols. 1-3, Cold Spring Harbor Laboratory; and Ausubel, et al. (eds.) (1993) Current Protocols in Molecular Biology, Greene and Wiley, NY. Techniques for synthesis of polypeptides are described, e.g., in Merrifield (1963) J. Amer. Chem. Soc. 85:2149-2156; Merrifield (1986) Science 20 232: 341-347; Atherton, et al. (1989) Solid Phase Peptide Synthesis: A Practical Approach, IRL Press, Oxford; and Grant (1992) Synthetic Peptides: A User's Guide, W.H. Freeman, NY. Refolding methods may be applicable to synthetic proteins.

25        This invention also contemplates the use of derivatives of IL-BKW proteins other than variations in amino acid sequence or glycosylation. Such derivatives may involve covalent or aggregative association with chemical moieties or protein carriers. Covalent or aggregative derivatives 30 will be useful as immunogens, as reagents in immunoassays, or in purification methods such as for affinity purification of binding partners, e.g., other antigens. An IL-BKW can be immobilized by covalent bonding to a solid support such as cyanogen bromide-activated SEPHAROSE, by methods which are 35 well known in the art, or adsorbed onto polyolefin surfaces, with or without glutaraldehyde cross-linking, for use in the

assay or purification of anti-IL-BKW antibodies or an alternative binding composition. The IL-BKW proteins can also be labeled with a detectable group, e.g., for use in diagnostic assays. Purification of IL-BKW may be effected  
5 by an immobilized antibody or complementary binding partner, e.g., binding portion of a receptor.

A solubilized IL-BKW or fragment of this invention can be used as an immunogen for the production of antisera or antibodies specific for binding. Purified antigen can be  
10 used to screen monoclonal antibodies or antigen-binding fragments, encompassing antigen binding fragments of natural antibodies, e.g., Fab, Fab', F(ab)<sub>2</sub>, etc. Purified IL-BKW antigens can also be used as a reagent to detect antibodies generated in response to the presence of elevated levels of  
15 the cytokine, which may be diagnostic of an abnormal or specific physiological or disease condition. This invention contemplates antibodies raised against amino acid sequences encoded by nucleotide sequence shown in SEQ ID NO: 1 of 5, or fragments of proteins containing it. In particular, this  
20 invention contemplates antibodies having binding affinity to or being raised against specific domains, e.g., helices A, B, C, or D.

The present invention contemplates the isolation of additional closely related species variants. Southern and  
25 Northern blot analysis will establish that similar genetic entities exist in other mammals. It is likely that IL-BKWs are widespread in species variants, e.g., rodents, lagomorphs, carnivores, artiodactyla, perissodactyla, and primates.

30 The invention also provides means to isolate a group of related antigens displaying both distinctness and similarities in structure, expression, and function. Elucidation of many of the physiological effects of the molecules will be greatly accelerated by the isolation and  
35 characterization of additional distinct species or polymorphic variants of them. In particular, the present

invention provides useful probes for identifying additional homologous genetic entities in different species.

The isolated genes will allow transformation of cells lacking expression of an IL-BKW, e.g., either species types 5 or cells which lack corresponding proteins and exhibit negative background activity. This should allow analysis of the function of IL-BKW in comparison to untransformed control cells.

Dissection of critical structural elements which effect 10 the various physiological functions mediated through these antigens is possible using standard techniques of modern molecular biology, particularly in comparing members of the related class. See, e.g., the homolog-scanning mutagenesis technique described in Cunningham, et al. (1989) Science 15 243:1339-1336; and approaches used in O'Dowd, et al. (1988) J. Biol. Chem. 263:15985-15992; and Lechleiter, et al. (1990) EMBO J. 9:4381-4390.

Intracellular functions would probably involve receptor signaling. However, protein internalization may occur under 20 certain circumstances, and interaction between intracellular components and cytokine may occur. Specific segments of interaction of IL-BKW with interacting components may be identified by mutagenesis or direct biochemical means, e.g., cross-linking or affinity methods. Structural analysis by 25 crystallographic or other physical methods will also be applicable. Further investigation of the mechanism of signal transduction will include study of associated components which may be isolatable by affinity methods or by genetic means, e.g., complementation analysis of mutants.

Further study of the expression and control of IL-BKW 30 will be pursued. The controlling elements associated with the antigens should exhibit differential physiological, developmental, tissue specific, or other expression patterns. Upstream or downstream genetic regions, e.g., 35 control elements, are of interest.

Structural studies of the IL-BKW antigens will lead to design of new antigens, particularly analogs exhibiting agonist or antagonist properties on the molecule. This can be combined with previously described screening methods to 5 isolate antigens exhibiting desired spectra of activities.

V. Antibodies

Antibodies can be raised to various epitopes of the IL-BKW proteins, including species, polymorphic, or allelic variants, and fragments thereof, both in their naturally 10 occurring forms and in their recombinant forms. Additionally, antibodies can be raised to IL-BKWs in either their active forms or in their inactive forms, including native or denatured versions. Anti-idiotypic antibodies are also contemplated.

15       Antibodies, including binding fragments and single chain versions, against predetermined fragments of the antigens can be raised by immunization of animals with conjugates of the fragments with immunogenic proteins. Monoclonal antibodies are prepared from cells secreting the 20 desired antibody. These antibodies can be screened for binding to normal or defective IL-BKWs, or screened for agonistic or antagonistic activity, e.g., mediated through a receptor. Antibodies may be agonistic or antagonistic, e.g., by sterically blocking binding to a receptor. These 25 monoclonal antibodies will usually bind with at least a  $K_D$  of about 1 mM, more usually at least about 300  $\mu$ M, typically at least about 100  $\mu$ M, more typically at least about 30  $\mu$ M, preferably at least about 10  $\mu$ M, and more preferably at least about 3  $\mu$ M or better.

30       The antibodies of this invention can also be useful in diagnostic applications. As capture or non-neutralizing antibodies, they can be screened for ability to bind to the antigens without inhibiting binding to a receptor. As neutralizing antibodies, they can be useful in competitive 35 binding assays. They will also be useful in detecting or quantifying IL-BKW protein or its receptors. See, e.g.,

Chan (ed.) (1987) Immunology: A Practical Guide, Academic Press, Orlando, FLA; Price and Newman (eds.) (1991) Principles and Practice of Immunoassay, Stockton Press, N.Y.; and Ngo (ed.) (1988) Nonisotopic Immunoassay, Plenum Press, N.Y. Cross absorptions or other tests will identify antibodies which exhibit various spectra of specificities, e.g., unique or shared species specificities.

Further, the antibodies, including antigen binding fragments, of this invention can be potent antagonists that bind to the antigen and inhibit functional binding, e.g., to a receptor which may elicit a biological response. They also can be useful as non-neutralizing antibodies and can be coupled to toxins or radionuclides so that when the antibody binds to antigen, a cell expressing it, e.g., on its surface, is killed. Further, these antibodies can be conjugated to drugs or other therapeutic agents, either directly or indirectly by means of a linker, and may effect drug targeting.

Antigen fragments may be joined to other materials, particularly polypeptides, as fused or covalently joined polypeptides to be used as immunogens. An antigen and its fragments may be fused or covalently linked to a variety of immunogens, such as keyhole limpet hemocyanin, bovine serum albumin, tetanus toxoid, etc. See Microbiology, Hoeber Medical Division, Harper and Row, 1969; Landsteiner (1962) Specificity of Serological Reactions, Dover Publications, New York; Williams, et al. (1967) Methods in Immunology and Immunochemistry, vol. 1, Academic Press, New York; and Harlow and Lane (1988) Antibodies: A Laboratory Manual, CSH Press, NY, for descriptions of methods of preparing polyclonal antisera.

In some instances, it is desirable to prepare monoclonal antibodies from various mammalian hosts, such as mice, rodents, primates, humans, etc. Description of techniques for preparing such monoclonal antibodies may be found in, e.g., Stites, et al. (eds.) Basic and Clinical

Immunology (4th ed.), Lange Medical Publications, Los Altos, CA, and references cited therein; Harlow and Lane (1988) Antibodies: A Laboratory Manual, CSH Press; Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed.), 5 Academic Press, New York; and particularly in Kohler and Milstein (1975) in Nature 256:495-497, which discusses one method of generating monoclonal antibodies.

Other suitable techniques involve in vitro exposure of lymphocytes to the antigenic polypeptides or alternatively 10 to selection of libraries of antibodies in phage or similar vectors. See, Huse, et al. (1989) "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," Science 246:1275-1281; and Ward, et al. (1989) Nature 341:544-546. The polypeptides and antibodies 15 of the present invention may be used with or without modification, including chimeric or humanized antibodies. Frequently, the polypeptides and antibodies will be labeled by joining, either covalently or non-covalently, a substance 20 which provides for a detectable signal. A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like. 25 Patents, teaching the use of such labels include U.S. Patent Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241. Also, recombinant immunoglobulins may be produced, see Cabilly, U.S. Patent No. 4,816,567; Moore, et al., U.S. Patent No. 4,642,334; and Queen, et al. 30 (1989) Proc. Nat'l Acad. Sci. USA 86:10029-10033.

The antibodies of this invention can also be used for affinity chromatography in isolating the protein. Columns can be prepared where the antibodies are linked to a solid support. See, e.g., Wilchek et al. (1984) Meth. Enzymol. 35 104:3-55.

Antibodies raised against each IL-BKW will also be useful to raise anti-idiotypic antibodies. These will be useful in detecting or diagnosing various immunological conditions related to expression of the respective antigens.

5 VI. Nucleic Acids

The described peptide sequences and the related reagents are useful in detecting, isolating, or identifying a DNA clone encoding IL-BKW, e.g., from a natural source. Typically, it will be useful in isolating a gene from 10 mammal, and similar procedures will be applied to isolate genes from other species, e.g., warm blooded animals, such as birds and mammals. Cross hybridization will allow isolation of IL-BKW from the same, e.g., polymorphic variants, or other species. A number of different 15 approaches should be available to successfully isolate a suitable nucleic acid clone.

The purified protein or defined peptides are useful for generating antibodies by standard methods, as described above. Synthetic peptides or purified protein can be 20 presented to an immune system to generate monoclonal or polyclonal antibodies. See, e.g., Coligan (1991) Current Protocols in Immunology Wiley/Greene; and Harlow and Lane (1989) Antibodies: A Laboratory Manual, Cold Spring Harbor Press.

25 For example, the specific binding composition could be used for screening of an expression library made from a cell line which expresses an IL-BKW. Screening of intracellular expression can be performed by various staining or immunofluorescence procedures. Binding compositions could 30 be used to affinity purify or sort out cells expressing a surface fusion protein.

The peptide segments can also be used to predict appropriate oligonucleotides to screen a library. The genetic code can be used to select appropriate 35 oligonucleotides useful as probes for screening. See, e.g., SEQ ID NO: 1 or 5. In combination with polymerase chain

reaction (PCR) techniques, synthetic oligonucleotides will be useful in selecting correct clones from a library. Complementary sequences will also be used as probes, primers, or antisense strands. Various fragments should be 5 particularly useful, e.g., coupled with anchored vector or poly-A complementary PCR techniques or with complementary DNA of other peptides.

This invention contemplates use of isolated DNA or fragments to encode a biologically active corresponding 10 IL-BKW polypeptide, particularly lacking the portion coding the untranslated 5' portion of the described sequence. In addition, this invention covers isolated or recombinant DNA which encodes a biologically active protein or polypeptide and which is capable of hybridizing under appropriate 15 conditions with the DNA sequences described herein. Said biologically active protein or polypeptide can be an intact antigen, or fragment, and have an amino acid sequence disclosed in, e.g., SEQ ID NO: 2 or 6, particularly a mature peptide of SEQ ID NO: 6, or secreted mature polypeptide of 20 SEQ ID NO: 2. Further, this invention covers the use of isolated or recombinant DNA, or fragments thereof, which encode proteins which exhibit high identity to a secreted IL-BKW. The isolated DNA can have the respective regulatory sequences in the 5' and 3' flanks, e.g., promoters, 25 enhancers, poly-A addition signals, and others.

An "isolated" nucleic acid is a nucleic acid, e.g., an RNA, DNA, or a mixed polymer, which is substantially separated from other components which naturally accompany a native sequence, e.g., ribosomes, polymerases, and/or 30 flanking genomic sequences from the originating species. The term embraces a nucleic acid sequence which has been removed from its naturally occurring environment, and includes recombinant or cloned DNA isolates and chemically synthesized analogs or analogs biologically synthesized by 35 heterologous systems. A substantially pure molecule includes isolated forms of the molecule. Generally, the

nucleic acid will be in a vector or fragment less than about 50 kb, usually less than about 30 kb, typically less than about 10 kb, and preferably less than about 6 kb.

An isolated nucleic acid will generally be a  
5 homogeneous composition of molecules, but will, in some embodiments, contain minor heterogeneity. This heterogeneity is typically found at the polymer ends or portions not critical to a desired biological function or activity.

A "recombinant" nucleic acid is defined either by its method of production or its structure. In reference to its method of production, e.g., a product made by a process, the process is use of recombinant nucleic acid techniques, e.g., involving human intervention in the nucleotide sequence,  
10 typically selection or production. Alternatively, it can be a nucleic acid made by generating a sequence comprising fusion of two fragments which are not naturally contiguous to each other, but is meant to exclude products of nature, e.g., naturally occurring mutants. Thus, e.g., products  
15 made by transforming cells with any unnaturally occurring vector is encompassed, as are nucleic acids comprising sequence derived using any synthetic oligonucleotide process. Such is often done to replace a codon with a redundant codon encoding the same or a conservative amino  
20 acid, while typically introducing or removing a sequence recognition site.  
25

Alternatively, it is performed to join together nucleic acid segments of desired functions to generate a single genetic entity comprising a desired combination of functions  
30 not found in the commonly available natural forms.

Restriction enzyme recognition sites are often the target of such artificial manipulations, but other site specific targets, e.g., promoters, DNA replication sites, regulation sequences, control sequences, or other useful features may  
35 be incorporated by design. A similar concept is intended for a recombinant, e.g., fusion, polypeptide. Specifically

included are synthetic nucleic acids which, by genetic code redundancy, encode polypeptides similar to fragments of these antigens, and fusions of sequences from various different species or polymorphic variants.

5 A significant "fragment" in a nucleic acid context is a contiguous segment of at least about 17 nucleotides, generally at least about 22 nucleotides, ordinarily at least about 29 nucleotides, more often at least about 35 nucleotides, typically at least about 41 nucleotides,

10 usually at least about 47 nucleotides, preferably at least about 55 nucleotides, and in particularly preferred embodiments will be at least about 60 or more nucleotides, e.g., 67, 73, 81, 89, 95, etc.

A DNA which codes for an IL-BKW protein will be  
15 particularly useful to identify genes, mRNA, and cDNA species which code for related or similar proteins, as well as DNAs which code for homologous proteins from different species. There are likely homologs in other species, including primates, rodents, canines, felines, and birds.  
20 Various IL-BKW proteins should be homologous and are encompassed herein. However, even proteins that have a more distant evolutionary relationship to the antigen can readily be isolated under appropriate conditions using these sequences if they are sufficiently homologous. Primate IL-BKW proteins are of particular interest.

Recombinant clones derived from the genomic sequences, e.g., containing introns, will be useful for transgenic studies, including, e.g., transgenic cells and organisms, and for gene therapy. See, e.g., Goodnow (1992) "Transgenic  
30 Animals" in Roitt (ed.) Encyclopedia of Immunology, Academic Press, San Diego, pp. 1502-1504; Travis (1992) Science 256:1392-1394; Kuhn, et al. (1991) Science 254:707-710; Capecchi (1989) Science 244:1288; Robertson (1987) (ed.) Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, IRL Press, Oxford; and Rosenberg (1992) J. Clinical Oncology 10:180-199.

Substantial homology, e.g., identity, in the nucleic acid sequence comparison context means either that the segments, or their complementary strands, when compared, are identical when optimally aligned, with appropriate 5 nucleotide insertions or deletions, in at least about 50% of the nucleotides, generally at least about 58%, ordinarily at least about 65%, often at least about 71%, typically at least about 77%, usually at least about 85%, preferably at least about 95 to 98% or more, and in particular 10 embodiments, as high as about 99% or more of the nucleotides. Alternatively, substantial homology exists when the segments will hybridize under selective hybridization conditions, to a strand, or its complement, typically using a sequence of IL-BKW, e.g., in SEQ ID NO: 1, 15 or 5. Typically, selective hybridization will occur when there is at least about 55% identity over a stretch of at least about 30 nucleotides, preferably at least about 75% over a stretch of about 25 nucleotides, and most preferably at least about 90% over about 20 nucleotides. See, Kanehisa 20 (1984) Nuc. Acids Res. 12:203-213. The length of identity comparison, as described, may be over longer stretches, and in certain embodiments will be over a stretch of at least about 17 nucleotides, usually at least about 28 nucleotides, typically at least about 40 nucleotides, and preferably at 25 least about 75 to 100 or more nucleotides.

Stringent conditions, in referring to homology in the hybridization context, will be stringent combined conditions of salt, temperature, organic solvents, and other parameters, typically those controlled in hybridization 30 reactions. Stringent temperature conditions will usually include temperatures in excess of about 30° C, usually in excess of about 37° C, typically in excess of about 55° C, preferably in excess of about 70° C. Stringent salt conditions will ordinarily be less than about 1000 mM, 35 usually less than about 400 mM, typically less than about 250 mM, preferably less than about 150 mM, including about

100, 50, or even 20 mM. However, the combination of parameters is much more important than the measure of any single parameter. See, e.g., Wetmur and Davidson (1968) J. Mol. Biol. 31:349-370.

5 IL-BKW from other mammalian species can be cloned and isolated by cross-species hybridization of closely related species. Homology may be relatively low between distantly related species, and thus hybridization of relatively closely related species is advisable. Alternatively,  
10 preparation of an antibody preparation which exhibits less species specificity may be useful in expression cloning approaches.

#### VII. Making IL-BKW; Mimetics

DNA which encodes the IL-BKW or fragments thereof can  
15 be obtained by chemical synthesis, screening cDNA libraries, or screening genomic libraries prepared from a wide variety of cell lines or tissue samples. See, e.g., Okayama and Berg (1982) Mol. Cell. Biol. 2:161-170; Gubler and Hoffman (1983) Gene 25:263-269; and Glover (ed.) (1984) DNA Cloning: A Practical Approach, IRL Press, Oxford. Alternatively, the sequences provided herein provide useful PCR primers or allow synthetic or other preparation of suitable genes encoding an IL-BKW; including naturally occurring embodiments.  
25 This DNA can be expressed in a wide variety of host cells for the synthesis of a full-length IL-BKW or fragments which can in turn, e.g., be used to generate polyclonal or monoclonal antibodies; for binding studies; for construction and expression of modified molecules; and for  
30 structure/function studies.

Vectors, as used herein, comprise plasmids, viruses, bacteriophage, integratable DNA fragments, and other vehicles which enable the integration of DNA fragments into the genome of the host. See, e.g., Pouwels, et al. (1985 and Supplements) Cloning Vectors: A Laboratory Manual, Elsevier, N.Y.; and Rodriguez, et al. (1988) (eds.) Vectors:

A Survey of Molecular Cloning Vectors and Their Uses,  
Buttersworth, Boston, MA.

For purposes of this invention, DNA sequences are operably linked when they are functionally related to each other. For example, DNA for a presequence or secretory leader is operably linked to a polypeptide if it is expressed as a preprotein or participates in directing the polypeptide to the cell membrane or in secretion of the polypeptide. A promoter is operably linked to a coding sequence if it controls the transcription of the polypeptide; a ribosome binding site is operably linked to a coding sequence if it is positioned to permit translation. Usually, operably linked means contiguous and in reading frame, however, certain genetic elements such as repressor genes are not contiguously linked but still bind to operator sequences that in turn control expression. See, e.g., Rodriguez, et al., Chapter 10, pp. 205-236; Balbas and Bolivar (1990) Methods in Enzymology 185:14-37; and Ausubel, et al. (1993) Current Protocols in Molecular Biology, Greene and Wiley, NY.

Representative examples of suitable expression vectors include pCDNA1; pCD, see Okayama, et al. (1985) Mol. Cell Biol. 5:1136-1142; pMC1neo Poly-A, see Thomas, et al. (1987) Cell 51:503-512; and a baculovirus vector such as pAC 373 or pAC 610. See, e.g., Miller (1988) Ann. Rev. Microbiol. 42:177-199.

It will often be desired to express an IL-BKW polypeptide in a system which provides a specific or defined glycosylation pattern. See, e.g., Luckow and Summers (1988) Bio/Technology 6:47-55; and Kaufman (1990) Meth. Enzymol. 185:487-511.

The IL-BKW, or a fragment thereof, may be engineered to be phosphatidyl inositol (PI) linked to a cell membrane, but can be removed from membranes by treatment with a phosphatidyl inositol cleaving enzyme, e.g., phosphatidyl inositol phospholipase-C. This releases the antigen in a

biologically active form, and allows purification by standard procedures of protein chemistry. See, e.g., Low (1989) Biochim. Biophys. Acta 988:427-454; Tse, et al. (1985) Science 230:1003-1008; and Brunner, et al. (1991) J. Cell Biol. 114:1275-1283.

Now that the IL-BKW has been characterized, fragments or derivatives thereof can be prepared by conventional processes for synthesizing peptides. These include processes such as are described in Stewart and Young (1984) 10 Solid Phase Peptide Synthesis, Pierce Chemical Co., Rockford, IL; Bodanszky and Bodanszky (1984) The Practice of Peptide Synthesis, Springer-Verlag, New York; Bodanszky (1984) The Principles of Peptide Synthesis, Springer-Verlag, New York; and Villafranca (ed.) (1991) Techniques in Protein 15 Chemistry II, Academic Press, San Diego, Ca.

#### VIII. Uses

The present invention provides reagents which will find use in diagnostic applications as described elsewhere herein, e.g., in IL-BKW mediated conditions, or below in the 20 description of kits for diagnosis.

This invention also provides reagents with significant therapeutic potential. The IL-BKW (naturally occurring or recombinant), fragments thereof, and antibodies thereto, along with compounds identified as having binding affinity 25 to IL-BKW, should be useful in the treatment of conditions associated with abnormal physiology or development, including inflammatory conditions. In particular, modulation of physiology of lymphoid cells will be achieved by appropriate therapeutic treatment using the compositions 30 provided herein. For example, a disease or disorder associated with abnormal expression or abnormal signaling by an IL-BKW should be a likely target for an agonist or antagonist. The new cytokine should play a role in regulation or development of hematopoietic cells, e.g., 35 lymphoid cells, which affect immunological responses, e.g., inflammation and/or autoimmune disorders.

In particular, the cytokine should mediate, in various contexts, cytokine synthesis by the cells, proliferation, etc. Antagonists of IL-BKW, such as mutein variants of a naturally occurring form of IL-BKW or blocking antibodies, 5 may provide a selective and powerful way to block immune responses, e.g., in situations as inflammatory or autoimmune responses, including rheumatoid arthritis, systemic lupus erythematosus (SLE), Hashimoto's autoimmune thyroiditis, as well as acute and chronic inflammatory responses, e.g., 10 inflammatory bowel disease. See also Samter, et al. (eds.) Immunological Diseases vols. 1 and 2, Little, Brown and Co. Modulated cytokine release by the naturally occurring secreted form of IL-BKW, which can be produced in large quantities by recombinant methods, or by blocking 15 antibodies, should be regulatable by reagents made available herein, e.g., in a transplantation rejection situation.

In addition, certain combination compositions would be useful, e.g., with other modulators of inflammation. Such other molecules may include steroids, other versions of 20 IL-10, including cellular species variants, or viral IL-10s, e.g., EBV or EHV, and all of their respective antagonists.

Various abnormal conditions are known in each of the cell types shown to produce IL-BKW mRNA by Northern blot analysis. See Berkow (ed.) The Merck Manual of Diagnosis and Therapy, Merck & Co., Rahway, N.J.; Thorn, et al. 25 Harrison's Principles of Internal Medicine, McGraw-Hill, N.Y.; and Weatherall, et al. (eds.) Oxford Textbook of Medicine, Oxford University Press, Oxford. Many other medical conditions and diseases involve activation by 30 macrophages or monocytes, and many of these will be responsive to treatment by an agonist or antagonist provided herein. See, e.g., Stites and Terr (eds. 1991) Basic and Clinical Immunology Appleton and Lange, Norwalk, Connecticut; and Samter, et al. (eds.) Immunological Diseases Little, Brown and Co. These problems should be 35

susceptible to prevention or treatment using compositions provided herein.

IL-BKW, antagonists, antibodies, etc., can be purified and then administered to a patient, veterinary or human.

- 5 These reagents can be combined for therapeutic use with additional active or inert ingredients, e.g., in conventional pharmaceutically acceptable carriers or diluents, e.g., immunogenic adjuvants, along with physiologically innocuous stabilizers, excipients, or
- 10 preservatives. These combinations can be sterile filtered and placed into dosage forms as by lyophilization in dosage vials or storage in stabilized aqueous preparations. This invention also contemplates use of antibodies or binding fragments thereof, including forms which are not complement
- 15 binding.

Drug screening using IL-BKW or fragments thereof can be performed to identify compounds having binding affinity to or other relevant biological effects on IL-BKW functions, including isolation of associated components. Subsequent biological assays can then be utilized to determine if the compound has intrinsic stimulating activity and is therefore a blocker or antagonist in that it blocks the activity of the cytokine. Likewise, a compound having intrinsic stimulating activity can activate the signal pathway and is thus an agonist in that it simulates the activity of IL-BKW. This invention further contemplates the therapeutic use of blocking antibodies to IL-BKW as antagonists and of stimulatory antibodies as agonists. This approach should be particularly useful with other IL-BKW species variants.

- 30 In addition, IL-BKW may play a role in leukemogenesis or in viral infections by, e.g., HTLV or herpesviruses. It is induced by infection with herpesvirus saimiri. The herpesvirus also encodes a homolog of the cytokine IL-17 (CTLA-8). Thus, the cytokine, or antagonists, may be useful
- 35 in anti-tumor therapy. The viral correlation may suggest that the cytokine may be important in viral infection or

proliferation processes, or oncology processes, e.g., oncogenic transformation and proliferative conditions, as cancers or leukemias. See, e.g., Thorn, et al. Harrison's Principles of Internal Medicine, McGraw-Hill, N.Y.

5 In addition, the cytokine appears to be expressed in kidney cell, and may play a significant role in that organ's function, e.g., ion exchange or blood pressure regulation. The cytokine may also have important water balance functions. The cytokine appears to have some expression in  
10 kidney.

The quantities of reagents necessary for effective therapy will depend upon many different factors, including means of administration, target site, physiological state of the patient, and other medicants administered. Thus,  
15 treatment dosages should be titrated to optimize safety and efficacy. Typically, dosages used *in vitro* may provide useful guidance in the amounts useful for in situ administration of these reagents. Animal testing of effective doses for treatment of particular disorders will  
20 provide further predictive indication of human dosage. Various considerations are described, e.g., in Gilman, et al. (eds.) (1990) Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 8th Ed., Pergamon Press; and Remington's Pharmaceutical Sciences, 17th ed. (1990), Mack  
25 Publishing Co., Easton, Penn. Methods for administration are discussed therein and below, e.g., for oral, intravenous, intraperitoneal, or intramuscular administration, transdermal diffusion, and others. Pharmaceutically acceptable carriers will include water,  
30 saline, buffers, and other compounds described, e.g., in the Merck Index, Merck & Co., Rahway, New Jersey. Dosage ranges would ordinarily be expected to be in amounts lower than 1 mM concentrations, typically less than about 10  $\mu$ M concentrations, usually less than about 100 nM, preferably  
35 less than about 10 pM (picomolar), and most preferably less than about 1 fM (femtomolar), with an appropriate carrier.

Slow release formulations, or a slow release apparatus will often be utilized for continuous or long term administration. See, e.g., Langer (1990) Science 249:1527-1533.

5 IL-BKW, fragments thereof, and antibodies to it or its fragments, antagonists, and agonists, may be administered directly to the host to be treated or, depending on the size of the compounds, it may be desirable to conjugate them to carrier proteins such as ovalbumin or serum albumin prior to  
10 their administration. Therapeutic formulations may be administered in many conventional dosage formulations. While it is possible for the active ingredient to be administered alone, it is preferable to present it as a pharmaceutical formulation. Formulations typically comprise  
15 at least one active ingredient, as defined above, together with one or more acceptable carriers thereof. Each carrier should be both pharmaceutically and physiologically acceptable in the sense of being compatible with the other ingredients and not injurious to the patient. Formulations  
20 include those suitable for oral, rectal, nasal, topical, or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the  
25 art of pharmacy. See, e.g., Gilman, et al. (eds.) (1990) Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 8th Ed., Pergamon Press; and Remington's Pharmaceutical Sciences, 17th ed. (1990), Mack Publishing Co., Easton, Penn.; Avis, et al. (eds.) (1993)  
30 Pharmaceutical Dosage Forms: Parenteral Medications, Dekker, New York; Lieberman, et al. (eds.) (1990) Pharmaceutical Dosage Forms: Tablets, Dekker, New York; and Lieberman, et al. (eds.) (1990) Pharmaceutical Dosage Forms: Disperse Systems, Dekker, New York. The therapy of this invention  
35 may be combined with or used in association with other

agents, e.g., other types of IL-10s, or their respective antagonists.

Both the naturally occurring and the recombinant form of the IL-BKWs of this invention are particularly useful in 5 kits and assay methods which are capable of screening compounds for binding activity to the proteins. Several methods of automating assays have been developed in recent years so as to permit screening of tens of thousands of compounds in a short period. See, e.g., Fodor, et al. 10 (1991) Science 251:767-773, which describes means for testing of binding affinity by a plurality of defined polymers synthesized on a solid substrate. The development of suitable assays can be greatly facilitated by the availability of large amounts of purified, soluble IL-BKW as 15 provided by this invention.

Other methods can be used to determine the critical residues in the IL-BKW-IL-BKW receptor interactions.

Mutational analysis can be performed, e.g., see Somoza, et al. 20 (1993) J. Exptl. Med. 178:549-558, to determine specific residues critical in the interaction and/or signaling. However, residues in the A and D helices are likely to be most important in receptor interaction.

For example, antagonists can normally be found once the antigen has been structurally defined, e.g., by tertiary 25 structure data. Testing of potential interacting analogs is now possible upon the development of highly automated assay methods using a purified IL-BKW. In particular, new agonists and antagonists will be discovered by using screening techniques described herein. Of particular 30 importance are compounds found to have a combined binding affinity for a spectrum of IL-BKW molecules, e.g., compounds which can serve as antagonists for species variants of IL-BKW.

One method of drug screening utilizes eukaryotic or 35 prokaryotic host cells which are stably transformed with recombinant DNA molecules expressing an IL-BKW. Cells may

be isolated which express an IL-BKW in isolation from other molecules. Such cells, either in viable or fixed form, can be used for standard binding partner binding assays. See also, Parce, et al. (1989) Science 246:243-247; and Owicki, 5 et al. (1990) Proc. Nat'l Acad. Sci. USA 87:4007-4011, which describe sensitive methods to detect cellular responses.

Another technique for drug screening involves an approach which provides high throughput screening for compounds having suitable binding affinity to an IL-BKW and 10 is described in detail in Geysen, European Patent Application 84/03564, published on September 13, 1984. First, large numbers of different small peptide test compounds are synthesized on a solid substrate, e.g., plastic pins or some other appropriate surface, see Fodor, 15 et al. (1991). Then all the pins are reacted with solubilized, unpurified or solubilized, purified IL-BKW, and washed. The next step involves detecting bound IL-BKW.

Rational drug design may also be based upon structural studies of the molecular shapes of the IL-BKW and other 20 effectors or analogs. Effectors may be other proteins which mediate other functions in response to binding, or other proteins which normally interact with IL-BKW, e.g., a receptor. One means for determining which sites interact with specific other proteins is a physical structure 25 determination, e.g., x-ray crystallography or 2 dimensional NMR techniques. These will provide guidance as to which amino acid residues form molecular contact regions, as modeled, e.g., against cellular IL-10. For a detailed description of protein structural determination, see, e.g., 30 Blundell and Johnson (1976) Protein Crystallography, Academic Press, New York.

#### IX. Kits

This invention also contemplates use of IL-BKW proteins, fragments thereof, peptides, and their fusion 35 products in a variety of diagnostic kits and methods for detecting the presence of another IL-BKW or binding partner.

Typically the kit will have a compartment containing either a defined IL-BKW peptide or gene segment or a reagent which recognizes one or the other, e.g., IL-BKW fragments or antibodies.

5 A kit for determining the binding affinity of a test compound to an IL-BKW would typically comprise a test compound; a labeled compound, for example a binding partner or antibody having known binding affinity for IL-BKW; a source of IL-BKW (naturally occurring or recombinant); and a  
10 means for separating bound from free labeled compound, such as a solid phase for immobilizing the molecule. Once compounds are screened, those having suitable binding affinity to the antigen can be evaluated in suitable biological assays, as are well known in the art, to  
15 determine whether they act as agonists or antagonists to the IL-BKW signaling pathway. The availability of recombinant IL-BKW polypeptides also provide well defined standards for calibrating such assays.

A preferred kit for determining the concentration of, 20 e.g., an IL-BKW in a sample would typically comprise a labeled compound, e.g., binding partner or antibody, having known binding affinity for the antigen, a source of cytokine (naturally occurring or recombinant) and a means for separating the bound from free labeled compound, e.g., a  
25 solid phase for immobilizing the IL-BKW. Compartments containing reagents, and instructions, will normally be provided.

Antibodies, including antigen binding fragments, specific for the IL-BKW or fragments are useful in  
30 diagnostic applications to detect the presence of elevated levels of IL-BKW and/or its fragments. Such diagnostic assays can employ lysates, live cells, fixed cells, immunofluorescence, cell cultures, body fluids, and further can involve the detection of antigens related to the antigen  
35 in serum, or the like. Diagnostic assays may be homogeneous (without a separation step between free reagent and antigen-

binding partner complex) or heterogeneous (with a separation step). Various commercial assays exist, such as radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), enzyme immunoassay (EIA), enzyme-multiplied 5 immunoassay technique (EMIT), substrate-labeled fluorescent immunoassay (SLFIA), and the like. See, e.g., Van Vunakis, et al. (1980) Meth Enzymol. 70:1-525; Harlow and Lane (1980) Antibodies: A Laboratory Manual, CSH Press, NY; and Coligan, et al. (eds.) (1993) Current Protocols in 10 Immunology, Greene and Wiley, NY.

Anti-idiotypic antibodies may have similar use to diagnose presence of antibodies against an IL-BKW, as such may be diagnostic of various abnormal states. For example, overproduction of IL-BKW may result in production of various 15 immunological reactions which may be diagnostic of abnormal physiological states, particularly in proliferative cell conditions such as cancer or abnormal activation or differentiation.

Frequently, the reagents for diagnostic assays are 20 supplied in kits, so as to optimize the sensitivity of the assay. For the subject invention, depending upon the nature of the assay, the protocol, and the label, either labeled or unlabeled antibody or binding partner, or labeled IL-BKW is provided. This is usually in conjunction with other 25 additives, such as buffers, stabilizers, materials necessary for signal production such as substrates for enzymes, and the like. Preferably, the kit will also contain instructions for proper use and disposal of the contents after use. Typically the kit has compartments for each 30 useful reagent. Desirably, the reagents are provided as a dry lyophilized powder, where the reagents may be reconstituted in an aqueous medium providing appropriate concentrations of reagents for performing the assay.

Many of the aforementioned constituents of the drug 35 screening and the diagnostic assays may be used without modification or may be modified in a variety of ways. For

example, labeling may be achieved by covalently or non-covalently joining a moiety which directly or indirectly provides a detectable signal. In any of these assays, the binding partner, test compound, IL-BKW, or antibodies

5 thereto can be labeled either directly or indirectly.

Possibilities for direct labeling include label groups:

radiolabels such as  $^{125}\text{I}$ , enzymes (U.S. Pat. No. 3,645,090) such as peroxidase and alkaline phosphatase, and fluorescent labels (U.S. Pat. No. 3,940,475) capable of monitoring the

10 change in fluorescence intensity, wavelength shift, or fluorescence polarization. Possibilities for indirect labeling include biotinylation of one constituent followed by binding to avidin coupled to one of the above label

groups.

15 There are also numerous methods of separating the bound from the free IL-BKW, or alternatively the bound from the free test compound. The IL-BKW can be immobilized on various matrixes followed by washing. Suitable matrixes include plastic such as an ELISA plate, filters, and beads.

20 See, e.g., Coligan, et al. (eds.) (1993) Current Protocols in Immunology, Vol. 1, Chapter 2, Greene and Wiley, NY.

Other suitable separation techniques include, without limitation, the fluorescein antibody magnetizable particle method described in Rattle, et al. (1984) Clin. Chem.

25 30:1457-1461, and the double antibody magnetic particle separation as described in U.S. Pat. No. 4,659,678.

Methods for linking proteins or their fragments to the various labels have been extensively reported in the literature and do not require detailed discussion here.

30 Many of the techniques involve the use of activated carboxyl groups either through the use of carbodiimide or active esters to form peptide bonds, the formation of thioethers by reaction of a mercapto group with an activated halogen such as chloroacetyl, or an activated olefin such as maleimide, 35 for linkage, or the like. Fusion proteins will also find use in these applications.

Another diagnostic aspect of this invention involves use of oligonucleotide or polynucleotide sequences taken from the sequence of an IL-BKW. These sequences can be used as probes for detecting levels of the IL-BKW message in samples from patients suspected of having an abnormal condition, e.g., inflammatory or autoimmune. Since the cytokine may be a marker or mediator for activation, it may be useful to determine the numbers of activated cells to determine, e.g., when additional therapy may be called for, e.g., in a preventative fashion before the effects become and progress to significance. The preparation of both RNA and DNA nucleotide sequences, the labeling of the sequences, and the preferred size of the sequences has received ample description and discussion in the literature. See, e.g., Langer-Safer, et al. (1982) Proc. Nat'l. Acad. Sci. 79:4381-4385; Caskey (1987) Science 236:962-967; and Wilchek et al. (1988). Anal. Biochem. 171:1-32.

Diagnostic kits which also test for the qualitative or quantitative expression of other molecules are also contemplated. Diagnosis or prognosis may depend on the combination of multiple indications used as markers. Thus, kits may test for combinations of markers. See, e.g., Viallet, et al. (1989) Progress in Growth Factor Res. 1:89-97. Other kits may be used to evaluate other cell subsets.

## 25 X. Isolating the IL-BKW Receptor

Having isolated a ligand of a specific ligand-receptor interaction, methods exist for isolating the receptor. See, Gearing, et al. (1989) EMBO J. 8:3667-3676. For example, means to label the IL-BKW cytokine without interfering with the binding to its receptor can be determined. For example, an affinity label can be fused to either the amino- or carboxyl-terminus of the ligand, though based on IL-10, the amino-terminus is more likely to succeed. Such label may be a FLAG epitope tag, or, e.g., an Ig or Fc domain. An expression library can be screened for specific binding of the cytokine, e.g., by cell sorting, or other screening to

detect subpopulations which express such a binding component. See, e.g., Ho, et al. (1993) Proc. Nat'l Acad. Sci. USA 90:11267-11271; and Liu, et al. (1994) J. Immunol. 152:1821-29. Alternatively, a panning method may be used.

5 See, e.g., Seed and Aruffo (1987) Proc. Nat'l Acad. Sci. USA 84:3365-3369.

Protein cross-linking techniques with label can be applied to isolate binding partners of the IL-BKW cytokine. This would allow identification of proteins which

10 specifically interact with the cytokine, e.g., in a ligand-receptor like manner.

Early experiments will be performed to determine whether the known IL-10R is involved in response(s) to IL-BKW. It is also quite possible that the functional IL-10

15 receptor complex may share many or all components with an IL-BKW receptor complex, either a specific receptor subunit or an accessory receptor subunit.

Many modifications and variations of this invention can be made without departing from its spirit and scope, as will

20 be apparent to those skilled in the art. The specific embodiments described herein are offered by way of example only, and the invention is to be limited only by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled.

25

#### EXAMPLES

##### General Methods

Some of the standard methods are described or referenced, e.g., in Maniatis, et al. (1982) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor Press; Sambrook, et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed.), vols. 1-3, CSH Press, NY; Ausubel, et al., Biology, Greene Publishing Associates, Brooklyn, NY; or Ausubel, et al. (1987 and Supplements)

30

35 Current Protocols in Molecular Biology, Greene and Wiley, New York; Innis, et al. (eds.) (1990) PCR Protocols: A Guide

to Methods and Applications, Academic Press, N.Y. Methods for protein purification include such methods as ammonium sulfate precipitation, column chromatography, electrophoresis, centrifugation, crystallization, and others. See, e.g., Ausubel, et al. (1987 and periodic supplements); Deutscher (1990) "Guide to Protein Purification" in Methods in Enzymology vol. 182, and other volumes in this series; and manufacturer's literature on use of protein purification products, e.g., Pharmacia, Piscataway, N.J., or Bio-Rad, Richmond, CA. Combination with recombinant techniques allow fusion to appropriate segments, e.g., to a FLAG sequence or an equivalent which can be fused via a protease-removable sequence. See, e.g., Hochuli (1989) Chemische Industrie 12:69-70; Hochuli (1990) "Purification of Recombinant Proteins with Metal Chelate Absorbent" in Setlow (ed.) Genetic Engineering, Principle and Methods 12:87-98, Plenum Press, N.Y.; and Crowe, et al. (1992) OIAexpress: The High Level Expression & Protein Purification System QUIAGEN, Inc., Chatsworth, CA. Cell culture techniques are described in Doyle, et al. (eds.) (1994) Cell and Tissue Culture: Laboratory Procedures, John Wiley and Sons, NY.

Standard immunological techniques are described, e.g., in Hertzenberg, et al. (eds. 1996) Weir's Handbook of Experimental Immunology vols. 1-4, Blackwell Science; Coligan (1991) Current Protocols in Immunology Wiley/Greene, NY; and Methods in Enzymology volumes. 70, 73, 74, 84, 92, 93, 108, 116, 121, 132, 150, 162, and 163.

FACS analyses are described in Melamed, et al. (1990) Flow Cytometry and Sorting Wiley-Liss, Inc., New York, NY; Shapiro (1988) Practical Flow Cytometry Liss, New York, NY; and Robinson, et al. (1993) Handbook of Flow Cytometry Methods Wiley-Liss, New York, NY. Fluorescent labeling of appropriate reagents was performed by standard methods.

35

EXAMPLE 1: Cloning of human and mouse IL-BKW

PBMC are prepared from a healthy human blood donor by conventional Ficoll gradients, as described, e.g., in Coligan, et al. Current Protocols in Immunology Greene/Wiley. Cells, preferably monocytes, from this preparation are stimulated, e.g., with PHA. RNA from these activated monocytes is used to isolate a cDNA based upon the sequence information about the mda7.

PCR products are cloned using a TA cloning kit (Invitrogen). The resulting cDNA plasmids are sequenced 10 from both termini on an automated sequencer (Applied Biosystems).

The clone for mIL-BKW was isolated from an NK1.1+, CD4+ activated mouse thymocyte cDNA library (A. Zlotnik, DNAX Research Institute, Palo Alto, CA). Sequencing of this 15 clone reveal high amino acid sequence identity to hIL-BKW as well as mIL-10 and hIL-10. In particular, a high degree of identity between the four cytokines was found in the D-helix domain, implicated in receptor binding.

20 EXAMPLE 2: Cellular Expression of Mammalian IL-BKW

Because of the sequence similarity to human IL-10, distribution will be investigated for similar type cell types. A probe specific for cDNA encoding primate IL-BKW is labeled, e.g., by random priming.

25 IL-BKW/ak155 is strongly transcribed in various T-cell tissues and clones.

Southern Analysis: DNA (5 µg) from the primary amplified cDNA library was digested with appropriate restriction enzymes to release the inserts, run on a 1% 30 agarose gel and transferred to a nylon membrane (Schleicher and Schuell, Keene, NH).

Multiple tissue Northern blots were used to determine the size and tissue distribution of hIL-BKW mRNA. A number of mRNA transcripts, varying in size from 1.0 kb to 4.4 kb, 35 were detected in most of the tissues. Based on the stringency of the hybridization and wash conditions of the

blots, these transcripts most likely represent alternatively spliced mRNA's and not different family members. A similar Northern blot using cancer cell lines (Clontech) revealed a strongly hybridizing 2.2 kb mRNA transcript in colorectal 5 carcinoma SW480, but that was not present in any of the other cancer lines.

The expression profile of hIL-BKW in monocytes/macrophages, dendritic, T, B, and NK cells was analysed by cDNA library Southern blot hybridization. The 10 hIL-BKW probe was hybridized to 5 µg of each cDNA library following digestion with NotI and SalI to release the cDNA inserts from the pSport vector (Gibco-BRL). Among T, B, and NK cells, expression of hIL-BKW was restricted to an activated Th0 clone (Mot72) and an activated Th1 clone 15 (HY06). By far the highest level of hIL-BKW expression was seen in elutriated monocytes activated with LPS, IFN-γ and anti-IL-10 antibodies. In contrast, when we probed a library made from these same monocytes treated with IL-10 instead of anti-IL10, a sharp decrease in the level of IL- 20 BKW expression was observed, suggesting that expression of IL-BKW is strongly regulated by IL-10.

Samples for mRNA isolation for analysis of mIL-BKW include: resting mouse fibroblastic L cell line (C200); Braf:ER (Braf fusion to estrogen receptor) transfected 25 cells, control (C201); T cells, TH1 polarized (Mel14 bright, CD4+ cells from spleen, polarized for 7 days with IFN-γ and anti IL-4; T200); T cells, TH2 polarized (Mel14 bright, CD4+ cells from spleen, polarized for 7 days with IL-4 and anti-IFN-γ; T201); T cells, highly TH1 polarized (see Openshaw, 30 et al. (1995) J. Exp. Med. 182:1357-1367; activated with anti-CD3 for 2, 6, 16 h pooled; T202); T cells, highly TH2 polarized (see Openshaw, et al. (1995) J. Exp. Med. 182:1357-1367; activated with anti-CD3 for 2, 6, 16 h pooled; T203); CD44- CD25+ pre T cells, sorted from thymus 35 (T204); TH1 T cell clone D1.1, resting for 3 weeks after last stimulation with antigen (T205); TH1 T cell clone D1.1,

10 µg/ml ConA stimulated 15 h (T206); TH2 T cell clone  
CDC35, resting for 3 weeks after last stimulation with  
antigen (T207); TH2 T cell clone CDC35, 10 µg/ml ConA  
stimulated 15 h (T208); Mel14+ naive T cells from spleen,  
5 resting (T209); Mel14+ T cells, polarized to Th1 with IFN- $\gamma$ /IL-12/anti-IL-4 for 6, 12, 24 h pooled (T210); Mel14+ T  
cells, polarized to Th2 with IL-4/anti-IFN- $\gamma$  for 6, 13, 24 h  
pooled (T211); unstimulated mature B cell leukemia cell line  
A20 (B200); unstimulated B cell line CH12 (B201);  
10 unstimulated large B cells from spleen (B202); B cells from  
total spleen, LPS activated (B203); metrizamide enriched  
dendritic cells from spleen, resting (D200); dendritic cells  
from bone marrow, resting (D201); monocyte cell line RAW  
264.7 activated with LPS 4 h (M200); bone-marrow macrophages  
15 derived with GM and M-CSF (M201); macrophage cell line J774,  
resting (M202); macrophage cell line J774 + LPS + anti-IL-10  
at 0.5, 1, 3, 6, 12 h pooled (M203); macrophage cell line  
J774 + LPS + IL-10 at 0.5, 1, 3, 5, 12 h pooled (M204);  
aerosol challenged mouse lung tissue, Th2 primed, aerosol  
20 OVA challenge 7, 14, 23 h pooled (see Garlisi, et al. (1995)  
Clinical Immunology and Immunopathology 75:75-83; X206);  
Nippostrongylus-infected lung tissue (see Coffman, et al.  
(1989) Science 245:308-310; X200); total adult lung, normal  
(O200); total lung, rag-1 (see Schwarz, et al. (1993)  
25 Immunodeficiency 4:249-252; O205); IL-10 K.O. spleen (see  
Kuhn, et al. (1991) Cell 75:263-274; X201); total adult  
spleen, normal (O201); total spleen, rag-1 (O207); IL-10  
K.O. Peyer's patches (O202); total Peyer's patches, normal  
(O210); IL-10 K.O. mesenteric lymph nodes (X203); total  
30 mesenteric lymph nodes, normal (O211); IL-10 K.O. colon  
(X203); total colon, normal (O212); NOD mouse pancreas (see  
Makino, et al. (1980) Jikken Dobutsu 29:1-13; X205); total  
thymus, rag-1 (O208); total kidney, rag-1 (O209); total  
heart, rag-1 (O202); total brain, rag-1 (O203); total  
35 testes, rag-1 (O204); total liver, rag-1 (O206); rat normal  
joint tissue (O300); and rat arthritic joint tissue (X300).

Expression by cDNA Southern analysis was very high in T cells, TH2 polarized (Mell14 bright, CD4+ cells from spleen, polarized for 7 days with IL-4 and anti-IFN- $\gamma$ ; T201); high in T cells, highly TH2 polarized (see Openshaw, et al.

5 (1995) J. Exp. Med. 182:1357-1367; activated with anti-CD3 for 2, 6, 16 h pooled; T203); and significant in: T cells, TH1 polarized (Mell14 bright, CD4+ cells from spleen, polarized for 7 days with IFN- $\gamma$  and anti IL-4; T200); and Mell14+ T cells, polarized to Th2 with IL-4/anti-IFN- $\gamma$  for 6, 10 13, 24 h pooled (T211).

**EXAMPLE 3: Chromosome mapping of mouse and human IL-BKW**

The mIL-BKW gene was mapped to mouse chromosome 1 using procedures well known in the art. See, e.g., Copeland, et al., (1993) Science 262:57-66. mIL-10 maps directly adjacent to mIL-BKW on chromosome 1.

To map the human counterpart, an isolated human IL-BKW cDNA encoding the IL-BKW is used. Chromosome mapping is a standard technique as described above. See, e.g., BIOS 20 Laboratories (New Haven, CT) and methods for using a mouse somatic cell hybrid panel with PCR. The human gene has been mapped to human Chromosome 1, and is likely, from mouse syntenic information, to the 1q32 region.

25 **EXAMPLE 4: Purification of IL-BKW Protein**

Multiple transfected cell lines are screened for one which expresses the cytokine at a high level compared with other cells. Various cell lines are screened and selected for their favorable properties in handling. Natural IL-BKW 30 can be isolated from natural sources, or by expression from a transformed cell using an appropriate expression vector. Purification of the expressed protein is achieved by standard procedures, or may be combined with engineered means for effective purification at high efficiency from 35 cell lysates or supernatants. FLAG or His6 segments can be used for such purification features. Alternatively,

affinity chromatography may be used with specific antibodies, see below.

Protein is produced in coli, insect cell, or mammalian expression systems. Production of mouse fusion protein as 5 an IgG fusion, with an IGase cleavage site, in COP5 cells resulted in secreted product which was N-terminal blocked. Microsequencing analysis indicated that the actual N- terminus was QEF.... Production of similar material with human sequence provides an N-terminus of AQG....

10 Recombinant human IL-BKW produced from a standard construct in mammalian cells seems to be found only in small amounts as a soluble form in the medium. Evidence exists that the protein binds tightly to cell surface proteoglycans, and is difficult to solubilize. Heparin 15 treatment causes some release of that protein. Surface proteoglycan deficient cells may be used to produce the protein.

#### EXAMPLE 5: Isolation of Homologous IL-BKW Genes

20 The IL-BKW cDNA can be used as a hybridization probe to screen a library from a desired source, e.g., a primate cell cDNA library. Many different species can be screened both for stringency necessary for easy hybridization, and for presence using a probe. Appropriate hybridization 25 conditions will be used to select for clones exhibiting specificity of cross hybridization.

Screening by hybridization using degenerate probes based upon the peptide sequences will also allow isolation of appropriate clones. Alternatively, use of appropriate 30 primers for PCR screening will yield enrichment of appropriate nucleic acid clones.

Similar methods are applicable to isolate either species, polymorphic, or allelic variants. Species variants are isolated using cross-species hybridization techniques 35 based upon isolation of a full length isolate or fragment from one species as a probe.

Alternatively, antibodies raised against human IL-BKW will be used to screen for cells which express cross-reactive proteins from an appropriate, e.g., cDNA library. The purified protein or defined peptides are useful for generating antibodies by standard methods, as described above. Synthetic peptides or purified protein are presented to an immune system to generate monoclonal or polyclonal antibodies. See, e.g., Coligan (1991) Current Protocols in Immunology Wiley/Greene; and Harlow and Lane (1989) Antibodies: A Laboratory Manual Cold Spring Harbor Press. The resulting antibodies are used for screening, purification, or diagnosis, as described.

EXAMPLE 6: Preparation of antibodies specific for IL-BKW  
15 Synthetic peptides or purified protein are presented to an immune system to generate monoclonal or polyclonal antibodies. See, e.g., Coligan (1991) Current Protocols in Immunology Wiley/Greene; and Harlow and Lane (1989) Antibodies: A Laboratory Manual Cold Spring Harbor Press.  
20 Polyclonal serum, or hybridomas may be prepared. In appropriate situations, the binding reagent is either labeled as described above, e.g., fluorescence or otherwise, or immobilized to a substrate for panning methods.  
25 A number of monoclonal antibodies were obtained. Of those which were purified; half were IgG and the other half were IgM. Most of these were good Western blot reagents. Several of the others stain recombinant hIL-BKW expressed on the cell surface, and others were 30 adequate for immunohistochemistry. "Positive" cells seen via the latter in tonsil sections appear to be macrophage-like.

EXAMPLE 7: IL-10 regulated expression of IL-BKW  
35 To investigate the regulatory effect of IL-10 directly by Northern blot analysis, mRNA was prepared from

elutriated, LPS and IFN- $\gamma$  activated monocytes, treated with either IL-10 or an anti-IL-10 antibody. Just as assessed by Southern blots of the cDNA libraries, strong induction of IL-BKW mRNA was observed in activated monocytes treated with 5 anti-IL-10, whereas treatment of these cells under identical conditions in the presence of IL-10 almost completely shut down synthesis of IL-BKW message.

EXAMPLE 8: Evaluation of Breadth of Biological Functions

10 Biological activities of IL-BKW were tested based on the sequence and structural homology between IL-BKW and IL-10. Initially, assays that had shown biological activities of IL-10 were examined. These include assays on human peripheral blood mononuclear cells, human monocytes, and 15 human T cell clones.

A. Effects on the expression of cell surface molecules on human monocytes.

Monocytes were purified by negative selection from 20 peripheral blood mononuclear cells of normal healthy donors. Briefly,  $3 \times 10^8$  ficoll banded mononuclear cells were incubated on ice with a cocktail of monoclonal antibodies (Becton-Dickenson; Mountain View, CA) consisting of 200  $\mu$ l of  $\alpha$ CD2 (Leu-5A), 200  $\mu$ l of  $\alpha$ CD3 (Leu-4), 100  $\mu$ l of  $\alpha$ CD8 25 (Leu 2a), 100  $\mu$ l of  $\alpha$ CD19 (Leu-12), 100  $\mu$ l of  $\alpha$ CD20 (Leu-16), 100  $\mu$ l of  $\alpha$ CD56 (Leu-19), 100  $\mu$ l of  $\alpha$ CD67 (IOM 67) (Immunotech, Westbrook, ME), and anti-glycophorin antibody (10F7MN, ATCC, Rockville, MD). Antibody bound cells were washed and then incubated with sheep anti-mouse IgG coupled 30 magnetic beads (Dynal, Oslo, Norway) at a bead to cell ratio of 20:1. Antibody bound cells were separated from monocytes by application of a magnetic field. Subsequently, human monocytes were cultured in Yssel's medium (Gemini Bioproducts, Calabasas, CA) containing 1% human AB serum in 35 the absence or presence of IL-BKW (1/100 dilution baculovirus expressed material or 1  $\mu$ g/ml mammalian cop 5

expressed material) or IL-10 (200 U/ml) in polypropylene 96 well plates (Costar) for 40 hrs. In addition, identical cultures were established in the presence of IFN- $\gamma$  (100 U/ml).

Analyses of the expression of cell surface molecules was performed by direct immunofluorescence. Briefly, 2 x 10<sup>5</sup> purified human monocytes were incubated in phosphate buffered saline (PBS) containing 1% human serum on ice for 20 minutes. Cells were pelleted at 200 x g. Cells were resuspended in 20 ml PE or FITC labeled mAb. Following an additional 20 minute incubation on ice, cells were washed in PBS containing 1% human serum followed by two washes in PBS alone. Cells were fixed in PBS containing 1% paraformaldehyde and analyzed on FACScan flow cytometer (Becton Dickenson; Mountain View, CA) and results are expressed as mean fluorescence intensity in Table 3. The following mAbs were used: CD11b (anti-mac1), CD11c (a gp150/95), CD14 (Leu-M3), CD54 (Leu 54), CD80 (anti-BB1/B7), HLA-DR (L243) from Becton-Dickinson and CD86 (FUN 1) (Pharmingen), CD64 (32.2) (Medarex), CD40 (mAb89) (Schering-Plough France).

TABLE 3

Effects of IL-BKW on the cell surface phenotype of human monocytes

	Exp 1	CD11B	CD14	CD54	CD80	CD86	HLA-DR	CD40
med-		261	976	159	16/33	395	1522	251
IL-BKW		202	1850	195	39/69	217	495	249
IFN-		307	365	262	93/87	277	3688	697
IFN + IL-BKW		222	275	342	97/268	375	4157	1299
	Exp 2							
t=0		668	1414	37	1	58	805	50
med-		293	1455	239	41/32	202	3130	152
IL-BKW		446	607	325	91/66	299	2190	123
IFN-		513	557	605	96/88	227	5664	481
IFN+ IL-BKW		485	529	633	98/181	338	7318	702

IL-BKW enhanced the expression of CD54 (ICAM-1), CD80, and CD86, whereas it decreased the expression of HLA-DR (see Table 3). IL-BKW further enhanced the upregulation of CD40, CD54, CD80, and CD86 by IFN- $\gamma$ . In the presence of IFN- $\gamma$ ,

5 IL-BKW enhanced the expression of HLA-DR. A variable effect of IL-BKW alone was observed on the expression of CD11b, CD11c, and CD14, whereas in combination with IFN- $\gamma$  it reduced cell surface expression as compared to IFN- $\gamma$  alone.

Since IL-10 downregulates CD54, CD80, CD86, and HLA-DR, both

10 in the presence or absence of IFN- $\gamma$ , these results indicate that IL-20 has different effects on the expression of cell surface molecules on monocytes as compared to IL-10.

15 B. Effects of IL-BKW on cytokine production by human monocytes.

Human monocytes were isolated as described and cultured in Yssel's medium (Gemini Bioproducts, Calabasas, CA) containing 1% human AB serum in the absence or presence of IL-BKW (1/100 dilution baculovirus expressed material). In

20 addition, monocytes were stimulated with the indicated amounts of LPS (E. coli 0127:B8 Difco) in the absence or presence of IL-BKW for 24 hrs and the concentration of cytokines (IL-1 $\beta$ , IL-6, TNF $\alpha$ , GM-CSF, and IL-10) in the cell culture supernatant was determined by ELISA. For

25 intracytoplasmic staining for cytokines, monocytes were cultured (1 million/ml) in Yssel's medium in the absence or presence of IL-BKW (1/100 dilution baculovirus expressed material or 1 mg/ml mammalian cop 5 expressed material) and/or 5 mg/ml LPS (E. coli 0127:B8 Difco) and 10 mg/ml

30 Brefeldin A (Epicentre technologies Madison WI) for 12 hrs. Cells were washed in PBS and incubated in 2% formaldehyde/PBS solution for 20 minutes at RT. Subsequently cells were washed, resuspended in permeabilization buffer (0.5% saponin (Sigma) in PBS/BSA

35 (0.5%) /Azide (1 mM)) and incubated for 20 minutes at RT. Cells ( $2 \times 10^5$ ) were centrifuged and resuspended in 20 ml directly conjugated anti-cytokine mAbs diluted 1:10 in

permeabilization buffer for 20 minutes at RT. The following antibodies were used: IL-1 $\alpha$  PE (364-3B3-14); IL-6-PE (MQ2-13A5); TNF $\alpha$ -PE (MAb11); GM-CSF-PE (BVD2-21C11); and IL-12-PE (C11.5.14) (Pharmingen San Diego, CA). Subsequently, cells  
5 were washed twice in permeabilization buffer and once in PBS/BSA/Azide and analyzed on FACScan flow cytometer (Becton Dickenson; Mountain View, CA). Results are expressed as % positive cells and mean fluorescence intensity of the positive population in Table 4.

10

TABLE 4

15 Effects of IL-BKW on cytokine production by human monocytes (% intracellular staining/mean fluorescence intensity)

	IL-1	IL-6	TNF
Medium	5	5	4
IL-BKW (1/100)	79/300	67/182	44/627
LPS (5 $\mu$ g/ml)	67/456	78/404	78/1524
LPS + IL-BKW	77/613	75/458	77/1573
	IL-1	IL-6	TNF
medium	9/58	39/65	7/159
IL-BKW (1 $\mu$ g/ml)	57/93	93/575	70/547
LPS (5 $\mu$ g/ml)	77/174	94/716	79/498
LPS + IL-BKW	79/172	96/1106	81/725

20 IL-BKW induced the expression of IL-6, TNF $\alpha$ , IL-10, IL-1b, and GM-CSF by human monocytes (Table 5). LPS also induced the expression of these cytokines in a dose dependent manner. Addition of IL-BKW in combination with LPS resulted in an enhanced production of IL-6, TNF $\alpha$ , IL-10, IL-1b, and GM-CSF as compared to either LPS or IL-BKW alone.

25

TABLE 5

## Effects of IL-BKW on cytokine production by human monocytes

5

	IL-1 $\beta$	IL-6	TNF	IL-10	GM-CSF
medium	0	2.229	0	0.007	0
LPS (ng/ml)	0.321	29	4.735	0.867	0.828
1000	0	36.78	4.683	1.417	0.371
100	0	37.06	2.156	1.216	0.080
10	0	36.22	0.806	0.918	0
1	1.460	27.9	1.808	0.391	0.673
IL-BKW (1/100)	4.637	93.02	12.09	2.332	2.048
+ LPS					
1000	3.921	82.56	9.843	3.994	1.309
100	4.024	142.2	5.708	3.096	1.466
10	2.744	85.66	4.006	2.58	0.852

(results expressed in ng/ml)

Similar results were obtained when cytokine production was assessed by intracytoplasmic staining. IL-BKW induced expression of IL-1, IL-6, and TNF $\alpha$  by human monocytes as indicated by an increase in the percentage of positive cells as well as the fluorescence intensity, which reflects the quantity of cytokine produced per cell. LPS induced the expression of IL-1, IL-6, and TNF $\alpha$ ; and addition of IL-BKW to these cultures further increased this production. This enhanced production was observed for both baculovirus and mammalian expressed material. See Table 4.

## 20 C. Effects of IL-BKW on cytokine production by human peripheral blood mononuclear cells (PBMC).

Total PBMC were isolated from buffy coats of normal healthy donors by centrifugation through ficoll-hypaque as described (Boyum, et al.) and cultured in Yssel's medium (Gemini Bioproducts, Calabasas, CA) containing 1% human AB serum in the absence or presence of IL-BKW (1/100 dilution baculovirus expressed material). Cells were incubated at  $2 \times 10^6$  cells/ml in medium or activated by PHA (100 ng/ml) or IL-2 (100 U/ml) (R&D Systems). In addition, PBMC were

cultured with IL-10 alone (100 U/ml) or IL-10 in combination with IL-BKW (1/100 dilution baculovirus expressed material). Cytokine secretion was determined in supernatants harvested at 72 hours by cytokine specific ELISA.

5

IL-BKW induced the expression of IL-6, TNF $\alpha$ , IL-10, and IFN- $\gamma$  by PBMC (see Table 6). Furthermore, IL-BKW enhanced the production of IL-6, TNF $\alpha$ , IL-10, and IFN- $\gamma$  when PBMC were activated by PHA or IL-2. IL-10 inhibited the production of IL-6, TNF $\alpha$ , and IFN- $\gamma$  following activation of PBMC by IL-BKW, PHA, IL-2, or combinations of IL-BKW with either PHA or IL-2.

15

TABLE 6

## Effects of IL-BKW on the cytokine production by PBMC

PBMC	IL-6	TNF $\alpha$	IL-10	IFN- $\gamma$
medium	0.243	0	0.007	0
IL-10 (100 U/ml)	0.196	0	NT	0
IL-BKW (1/100)	24.23	0.029	1.295	0.004
IL-10 + IL-BKW	0.339	0	NT	0
PHA (100 ng/ml)	5.491	0.652	0.637	1.05
IL-10	0.279	0	NT	0.004
IL-BKW	67.06	3.31	4.556	5.742
IL-10 + IL-BKW	1.129	0	NT	0.1
IL-2 (100 U/ml)	41.4	0.216	3.224	0.895
IL-10	0.89	0	NT	0.01
IL-BKW	62.34	0.621	10.04	1.507
IL-10 + IL-BKW	3.456	0	NT	0.081

results expressed in ng/ml; NT: not tested.

20

## D. Effects of IL-BKW on proliferation of human peripheral blood mononuclear cells (PBMC).

Total PBMC were isolated from buffy coats of normal healthy donors by centrifugation through ficoll-hypaque as described (Boyum, et al.). PBMC were cultured in 200 ml Yssel's medium (Gemini Bioproducts, Calabasas, CA) containing 1% human AB serum in 96 well plates (Falcon,

Becton-Dickinson, NJ) in the absence or presence of indicated amounts of IL-BKW (mammalian cop 5 expressed material). Cells were cultured in medium alone or in combination with 100 U/ml IL-2 (R&D Systems) for 120 hours.

5 3H-Thymidine (0.1 mCi) was added during the last six hours of culture and 3H-Thymidine incorporation was determined by liquid scintillation counting. Results are expressed as mean cpm of triplicate cultures.

10 IL-BKW induces a low level of proliferation of PBMC in a dose dependent manner. See Table 7. In addition, IL-BKW enhances also in a dose dependent manner the proliferative response of PBMC to IL-2.

TABLE 7

## 15 Effect of IL-BKW on proliferation by PBMC

IL-BKW (ng/ml)	MEAN	S.D.	+ IL-2 (100 U/ml)	MEAN	S.D.
1000	5894	2655		43426	12858
333	6430	1877		48187	2470
111	3510	1384		36435	5058
37	1016	331		24859	6014
12	235	60		22738	3379
4	190	75		23323	4266
1.3	175	49		22528	2979
0	100	4		17961	3839

results expressed as cpm +/- standard deviation

20 The native, recombinant, and fusion proteins would be tested for agonist and antagonist activity in many other biological assay systems, e.g., on T-cells, B-cells, NK, macrophages, dendritic cells, hematopoietic progenitors, etc. Because of the IL-10 structural relationship, assays related to IL-10 activity would analyzed

IL-BKW is evaluated for agonist or antagonist activity 25 on transfected cells expressing IL-10 receptor and controls. See, e.g., Ho, et al. (1993) Proc. Nat'l Acad. Sci. USA 90, 11267-11271; Ho, et al. (1995) Mol. Cell. Biol. 15:5043-5053; and Liu, et al. (1994). J. Immunol. 152:1821-1829.

Based, in part, upon the structural homology to IL-10, the IL-BKW is evaluated for effect in macrophage/dendritic cell activation and antigen presentation assays, T cell cytokine production and proliferation in response to antigen or allogeneic stimulus. See, e.g., de Waal Malefyt et al. (1991) J. Exp. Med. 174:1209-1220; de Waal Malefyt et al. (1991) J. Exp. Med. 174:915-924; Fiorentino, et al. (1991) J. Immunol. 147, 3815-3822; Fiorentino, et al. (1991) J. Immunol. 146:3444-3451; and Groux, et al. (1996) J. Exp. Med. 184:19-29.

IL-BKW will also be evaluated for effects on NK cell stimulation. Assays may be based, e.g., on Hsu, et al. (1992) Internat. Immunol. 4:563-569; and Schwarz, et al. (1994) J. Immunother. 16:95-104.

B cell growth and differentiation effects will be analyzed, e.g., by the methodology described, e.g., in Defrance, et al. (1992). J. Exp. Med. 175:671-682; Rousset, et al (1992) Proc. Nat'l Acad. Sci. USA 89:1890-1893; including IgG2 and IgA2 switch factor assays. Note that, unlike COS7 supernatants, NIH3T3 and COP supernatants apparently do not interfere with human B cell assays.

All references cited herein are incorporated herein by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference in its entirety for all purposes.

Many modifications and variations of this invention can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. The specific embodiments described herein are offered by way of example only, and the invention is to be limited only by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

5

(i) APPLICANT: Schering Corporation

(ii) TITLE OF INVENTION: Mammalian Cytokine; Related Reagents

10 (iii) NUMBER OF SEQUENCES: 7

(iv) CORRESPONDENCE ADDRESS:

- (A) ADDRESSEE: Schering-Plough Corporation
- (B) STREET: 2000 Galloping Hill Road
- (C) CITY: Kenilworth
- (D) STATE: NJ
- (E) COUNTRY: USA
- (F) ZIP: 07033

20 (v) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: Apple Macintosh
- (C) OPERATING SYSTEM: Macintosh 7.1
- (D) SOFTWARE: Microsoft Word 7.5.3

25

(vi) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER: PCT
- (B) FILING DATE: 22-DEC-1997
- (C) CLASSIFICATION:

30

(vii) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: US 60/034,151
- (B) FILING DATE: 23-DEC-1996

35

(viii) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: US 08/842,659
- (B) FILING DATE: 15-APR-1997

40

(ix) ATTORNEY/AGENT INFORMATION:

- (A) NAME: FOULKE, CYNTHIA L.
- (B) REGISTRATION NUMBER: 32,364
- (C) REFERENCE/DOCKET NUMBER: DX0683K

45

(x) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: (908) 298-2987
- (B) TELEFAX: (908) 298-5388

50

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1700 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

5 (ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 275..892

(ix) FEATURE:

10 (A) NAME/KEY: mat\_peptide  
(B) LOCATION: 419..892

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

15	CTTGCCCTGCA AACCTTTACT TCTGAAATGA CTTCCACGGC TGGGACGGGA ACCTTCCACC	60
	CACAGCTATG CCTCTGATTG GTGAATGGTG AAGGTGCCTG TCTAACCTTT CTGTAAAAAG	120
20	AACCAGCTGC CTCCAGGCAG CCAGCCCTCA AGCATCACTT ACAGGACCAAG AGGGACAAGA	180
	CATGACTGTG ATGAGGAGCT GCTTCGCCA ATTTAACACC AAGAAGAATT GAGGCTGCTT	240
	GGGAGGAAGG CCAGGAGGAA CACGAGACTG AGAG ATG AAT TTT CAA CAG AGG	292
25	Met Asn Phe Gln Gln Arg -48 -45	
	CTG CAA AGC CTG TGG ACT TTA GCC AGA CCC TTC TGC CCT CCT TTG CTG	340
	Leu Gln Ser Leu Trp Thr Leu Ala Arg Pro Phe Cys Pro Pro Leu Leu	
30	-40 -35 -30	
	GCG ACA GCC TCT CAA ATG CAG ATG GTT GTG CTC CCT TGC CTG GGT TTT	388
	Ala Thr Ala Ser Gln Met Gln Val Val Leu Pro Cys Leu Gly Phe	
	-25 -20 -15	
35	ACC CTG CTT CTC TGG AGC CAG GTA TCA GGG GCC CAG GGC CAA GAA TTC	436
	Thr Leu Leu Trp Ser Gln Val Ser Gly Ala Gln Gly Gln Glu Phe	
	-10 -5 1 5	
40	CAC TTT GGG CCC TGC CAA GTG AAG GGG GTT CCC CAG AAA CTG TGG	484
	His Phe Gly Pro Cys Gln Val Lys Gly Val Val Pro Gln Lys Leu Trp	
	10 15 20	
	GAA GCC TTC TGG GCT GTG AAA GAC ACT ATG CAA GCT CAG GAT AAC ATC	532
45	Glu Ala Phe Trp Ala Val Lys Asp Thr Met Gln Ala Gln Asp Asn Ile	
	25 30 35	
	ACG AGT GCC CGG CTG CTG CAG CAG GAG GTT CTG CAG AAC GTC TCG GAT	580
	Thr Ser Ala Arg Leu Leu Gln Gln Glu Val Leu Gln Asn Val Ser Asp	
50	40 45 50	
	GCT GAG AGC TGT TAC CTT GTC CAC ACC CTG CTG GAG TTC TAC TTG AAA	628
	Ala Glu Ser Cys Tyr Leu Val His Thr Leu Leu Glu Phe Tyr Leu Lys	
	55 60 65 70	

	ACT GTT TTC AAA AAC TAC CAC AAT AGA ACA GTT GAA GTC AGG ACT CTG	676
	Thr Val Phe Lys Asn Tyr His Asn Arg Thr Val Glu Val Arg Thr Leu	
5	75 80 85	
	AAG TCA TTC TCT ACT CTG GCC AAC AAC TTT GTT CTC ATC GTG TCA CAA	724
	Lys Ser Phe Ser Thr Leu Ala Asn Asn Phe Val Leu Ile Val Ser Gln	
	90 95 100	
10	CTG CAA CCC AGT CAA GAA AAT GAG ATG TTT TCC ATC AGA GAC AGT GCA	772
	Leu Gln Pro Ser Gln Glu Asn Glu Met Phe Ser Ile Arg Asp Ser Ala	
	105 110 115	
15	CAC AGG CGG TTT CTG CTA TTC CGG AGA GCA TTC AAA CAG TTG GAC GTA	820
	His Arg Arg Phe Leu Leu Phe Arg Arg Ala Phe Lys Gln Leu Asp Val	
	120 125 130	
20	GAA GCA GCT CTG ACC AAA GCC CTT CGG GAA GTG GAC ATT CTT CTG ACC	868
	Glu Ala Ala Leu Thr Lys Ala Leu Gly Glu Val Asp Ile Leu Leu Thr	
	135 140 145 150	
	TGG ATG CAG AAA TTC TAC AAG CTC TGAATGTCTA GACCAGGACC TCCCTCCCCC	922
	Trp Met Gln Lys Phe Tyr Lys Leu	
	155	
25	TGGCACTGGT TTGTTCCCTG TGTCATTCA AACAGTCTCC CTTCTATGC TGTTCACTGG	982
	ACACTTCACG CCCTTGGCCA TGGGTCCCAT TCTTGCCCCA GGATTATTGT CAAAGAAC	1042
30	ATTCTTTAAG CAGCGCCAGT GACAGTCAGG GAAGGTGCCT CTGGATGCTG TGAAGAGTCT	1102
	ACAGAGAAGA TTCTTGATT TATTACAAT CTATTTAATT AATGTCAGTA TTTCAACTGA	1162
	AGTTCTATT ATTGTGAGA CTGTAAGTTA CATGAAGGCA GCAGAATATT GTGCCCATG	1222
35	CTTCTTTACC CCTCACAAATC CTTGCCACAG TGTGGGCAG TGGATGGGTG CTTAGTAAGT	1282
	ACTTAATAAA CTGTGGTGCT TTTTTGGCC TGTCTTGGA TTGTTAAAAA ACAGAGAGGG	1342
40	ATGCTTGGAT GTAAAATGA ACTTCAGAGC ATGAAAATCA CACTGTCTGC TGATATCTGC	1402
	AGGGACAGAG CATTGGGTG GGGGTAAGGT GCATCTGTTT GAAAAGTAAA CGATAAAATG	1462
	TGGATTAAAG TGCCCAGCAC AAAGCAGATC CTCATAAAC ATTCATTTC CCACCCACAC	1522
45	TCGCCAGCTC ACCCCATCAT CCCTTCCCT TGGTGCCTC CTTTTTTTT TATCCTAGTC	1582
	ATTCTTCCCT AATCTTCCAC TTGAGTGTCA AGCTGACCTT GCTGATGGTG ACATTGCACC	1642
50	TGGATGTACT ATCCAATCTG TGATGACATT CCCTGCTAAT AAAAGACAAC ATAACCTCA	1700

(2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 206 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant

5

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

10 Met Asn Phe Gln Gln Arg Leu Gln Ser Leu Trp Thr Leu Ala Arg Pro  
     -48           -45                   -40                   -35

Phe Cys Pro Pro Leu Leu Ala Thr Ala Ser Gln Met Gln Met Val Val  
     -30           -25                   -20

15 Leu Pro Cys Leu Gly Phe Thr Leu Leu Trp Ser Gln Val Ser Gly  
     -15           -10                   -5

Ala Gln Gly Gln Glu Phe His Phe Gly Pro Cys Gln Val Lys Gly Val  
 20      1            5                10                   15

Val Pro Gln Lys Leu Trp Glu Ala Phe Trp Ala Val Lys Asp Thr Met  
     20            25                   30

25 Gln Ala Gln Asp Asn Ile Thr Ser Ala Arg Leu Leu Gln Gln Glu Val  
     35            40                   45

Leu Gln Asn Val Ser Asp Ala Glu Ser Cys Tyr Leu Val His Thr Leu  
     50            55                   60

30 Leu Glu Phe Tyr Leu Lys Thr Val Phe Lys Asn Tyr His Asn Arg Thr  
     65            70                   75                   80

Val Glu Val Arg Thr Leu Lys Ser Phe Ser Thr Leu Ala Asn Asn Phe  
 35        85                   90                   95

Val Leu Ile Val Ser Gln Leu Gln Pro Ser Gln Glu Asn Glu Met Phe  
     100           105                  110

40 Ser Ile Arg Asp Ser Ala His Arg Arg Phe Leu Leu Phe Arg Arg Ala  
     115           120                  125

Phe Lys Gln Leu Asp Val Glu Ala Ala Leu Thr Lys Ala Leu Gly Glu  
     130           135                  140

45 Val Asp Ile Leu Leu Thr Trp Met Gln Lys Phe Tyr Lys Leu  
     145           150                  155

## (2) INFORMATION FOR SEQ ID NO:3:

50

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 178 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Met His Ser Ser Ala Leu Leu Cys Cys Leu Val Leu Leu Thr Gly Val  
1 5 10 15

10 Arg Ala Ser Pro Gly Gln Gly Thr Gln Ser Glu Asn Ser Cys Thr His  
20 25 30

Phe Pro Gly Asn Leu Pro Asn Met Leu Arg Asp Leu Arg Asp Ala Phe  
35 40 45

15 Ser Arg Val Lys Thr Phe Phe Gln Met Lys Asp Gln Leu Asp Asn Leu  
50 55 60

Leu Leu Lys Glu Ser Leu Leu Glu Asp Phe Lys Gly Tyr Leu Gly Cys  
20 65 70 75 80

Gln Ala Leu Ser Glu Met Ile Gln Phe Tyr Leu Glu Glu Val Met Pro  
85 90 95

25 Gln Ala Glu Asn Gln Asp Pro Asp Ile Lys Ala His Val Asn Ser Leu  
100 105 110

Gly Glu Asn Leu Lys Thr Leu Arg Leu Arg Leu Arg Arg Cys His Arg  
115 120 125

30 Phe Leu Pro Cys Glu Asn Lys Ser Lys Ala Val Glu Gln Val Lys Asn  
130 135 140

Ala Phe Asn Lys Leu Gln Glu Lys Gly Ile Tyr Lys Ala Met Ser Glu  
35 145 150 155 160

Phe Asp Ile Phe Ile Asn Tyr Ile Glu Ala Tyr Met Thr Met Lys Ile  
165 170 175

40 Arg Asn

(2) INFORMATION FOR SEQ ID NO:4:

45 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 171 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

50 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:



	TATCAGGCCA GACGTTTGTG TGGTCCTATG GTAGTCTCAA AGCAGAGTGC ATGGTATCAT	60
	GTGGCAGGAA GGCA CGGACA AAGCTGAGCT GAAGTGGTTT TCACAAAGTA CCCACTCCAA	120
5	TGCATACATT CATGGTTTG TTTAAGAGGG CAGAGATCTG GTAACAGATC TGGGTGTAAG	180
	TTCCGAGTCA GAATTTGACT TCAGGGTAAA GCCTTCCTTT CTTCAGCAGG AGCACTGGCC	240
	CTTTCTTCAA CACAG ATG AGT TGG GGA CTA CAG ATT CTC CCC TGC CTG AGC	291
10	Met Ser Trp Gly Leu Gln Ile Leu Pro Cys Leu Ser	
	-23 -20 -15	
	CTA ATC CTT CTT CTT TGG AAC CAA GTG CCA GGG CTT GAG GGT CAA GAG	339
	Leu Ile Leu Leu Leu Trp Asn Gln Val Pro Gly Leu Glu Gly Gln Glu	
15	-10 -5 1 5	
	TTC CGA TCG GGG TCT TGC CAA GTG ACA GGG GTG GTT CTC CCA GAA CTG	387
	Phe Arg Ser Gly Ser Cys Gln Val Thr Gly Val Val Leu Pro Glu Leu	
	10 15 20	
20	TGG GAG GCC TTC TGG ACT GTG AAG AAC ACT GTG CAA ACT CAG GAT GAC	435
	Trp Glu Ala Phe Trp Thr Val Lys Asn Thr Val Gln Thr Gln Asp Asp	
	25 30 35	
25	ATC ACA AGC ATC CGG CTG TTG AAG CCG CAG GTT CTG CCG AAT GTC TCG	483
	Ile Thr Ser Ile Arg Leu Leu Lys Pro Gln Val Leu Arg Asn Val Ser	
	40 45 50	
	GGT GCT GAG AGC TGT TAC CTT GCC CAC AGC CTG CTG AAG TTC TAC TTG	531
30	Gly Ala Glu Ser Cys Tyr Leu Ala His Ser Leu Leu Lys Phe Tyr Leu	
	55 60 65	
	AAC ACT GTT TTC AAG AAC TAC CAC AGC AAA ATA GCC AAA TTC AAG GTC	579
	Asn Thr Val Phe Lys Asn Tyr His Ser Lys Ile Ala Lys Phe Lys Val	
35	70 75 80 85	
	TTG AGG TCA TTC TCC ACT CTG GCC AAC AAC TTC ATA GTC ATC ATG TCA	627
	Leu Arg Ser Phe Ser Thr Leu Ala Asn Asn Phe Ile Val Ile Met Ser	
	90 95 100	
40	CAA CTA CAG CCC AGT AAG GAC AAT TCC ATG CTT CCC ATT AGT GAG AGT	675
	Gln Leu Gln Pro Ser Lys Asp Asn Ser Met Leu Pro Ile Ser Glu Ser	
	105 110 115	
45	GCA CAC CAG CGG TTT TTG CTG TTC CGC AGA GCA TTC AAA CAG TTG GAT	723
	Ala His Gln Arg Phe Leu Leu Phe Arg Arg Ala Phe Lys Gln Leu Asp	
	120 125 130	
50	ACA GAA GTC GCT TTG GTG AAA GCC TTT GGG GAA GTG GAC ATT CTC CTG	771
	Thr Glu Val Ala Leu Val Lys Ala Phe Gly Glu Val Asp Ile Leu Leu	
	135 140 145	

	ACC TGG ATG CAG AAA TTC TAC CAT CTC TGACTGCTGA TTGGATAACT	818
	Thr Trp Met Gln Lys Phe Tyr His Leu	
150	155	
5	TCCTCCTTGTCTCCATGC CATTCAAGG CATTGTGTAC ATCCCTGCTG TCCTCAAGGC	878
	ACTTCAGACC CTTGGCCATG GACCCCGTTG TTGGCTCAGG CTTTCCTCA GACCTCACTC	938
10	TTCAGTCCAA ATGACAGCCA TAGATGGCAC CTTTGGATGC TCCGACTGAC CCACAAAGTA	998
	GATTTGCATA TTTATTACAG CCCTATTAAA TTATTGTAC CTTCCCTGGA AACCGTATTT	1058
	ATTTGTGAGA CCAGAAGTTC CATGAAAGCA TCAGAATTAA GTGCCCATG CCTCCTCCTC	1118
15	ACTTCCTGTG ATCTGGCTCA GCATGGGGGC AGTGGATGGT TGCTCAGTAA ATATTTAAAAA	1178
	TGGAAAAAAAAA AAAAAAAAAA	1197

20 (2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 181 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

	Met Ser Trp Gly Leu Gln Ile Leu Pro Cys Leu Ser Leu Ile Leu Leu		
-23	-20	-15	-10
35	Leu Trp Asn Gln Val Pro Gly Leu Glu Gly Gln Glu Phe Arg Ser Gly		
	-5	1	5
	Ser Cys Gln Val Thr Gly Val Val Leu Pro Glu Leu Trp Glu Ala Phe		
10	15	20	25
40	Trp Thr Val Lys Asn Thr Val Gln Thr Gln Asp Asp Ile Thr Ser Ile		
	30	35	40
	Arg Leu Leu Lys Pro Gln Val Leu Arg Asn Val Ser Gly Ala Glu Ser		
45	45	50	55
	Cys Tyr Leu Ala His Ser Leu Leu Lys Phe Tyr Leu Asn Thr Val Phe		
	60	65	70
50	Lys Asn Tyr His Ser Lys Ile Ala Lys Phe Lys Val Leu Arg Ser Phe		
	75	80	85
	Ser Thr Leu Ala Asn Asn Phe Ile Val Ile Met Ser Gln Leu Gln Pro		
	90	95	100
	105		

Ser Lys Asp Asn Ser Met Leu Pro Ile Ser Glu Ser Ala His Gln Arg  
 110 115 120

5 Phe Leu Leu Phe Arg Arg Ala Phe Lys Gln Leu Asp Thr Glu Val Ala  
 125 130 135

Leu Val Lys Ala Phe Gly Glu Val Asp Ile Leu Leu Thr Trp Met Gln  
 140 145 150

10 Lys Phe Tyr His Leu  
 155

(2) INFORMATION FOR SEQ ID NO:7:

15 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 178 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

25 Met Pro Gly Ser Ala Leu Leu Cys Cys Leu Leu Leu Thr Gly Met  
 1 5 10 15

Arg Ile Ser Arg Gly Gln Tyr Ser Arg Glu Asp Asn Asn Cys Thr His  
 20 25 30

30 Phe Pro Val Gly Gln Ser His Met Leu Leu Glu Leu Arg Thr Ala Phe  
 35 40 45

35 Ser Gln Val Lys Thr Phe Phe Gln Thr Lys Asp Gln Leu Asp Asn Ile  
 50 55 60

Leu Leu Thr Asp Ser Leu Met Gln Asp Phe Lys Gly Tyr Leu Gly Cys  
 65 70 75 80

40 Gln Ala Leu Ser Glu Met Ile Gln Phe Tyr Leu Val Glu Val Met Pro  
 85 90 95

Gln Ala Glu Lys His Gly Pro Glu Ile Lys Glu His Leu Asn Ser Leu  
 100 105 110

45 Gly Glu Lys Leu Lys Thr Leu Arg Met Arg Leu Arg Arg Cys His Arg  
 115 120 125

50 Phe Leu Pro Cys Glu Asn Lys Ser Lys Ala Val Glu Gln Val Lys Ser  
 130 135 140

Asp Phe Asn Lys Leu Gln Asp Gln Gly Val Tyr Lys Ala Met Asn Glu  
 145 150 155 160

Phe Asp Ile Phe Ile Asn Cys Ile Glu Ala Tyr Met Met Ile Lys Met  
165                           170                           175

Lys Ser

## WHAT IS CLAIMED IS:

1. A substantially pure or recombinant soluble IL-BKW protein.
- 5 2. An antigenic protein or peptide fragment of the IL-BKW of claim 1.
- 10 3. The IL-BKW of claim 2, which is a full length natural soluble protein from a mammal, including a primate or mouse.
4. The IL-BKW of claim 2, which:
  - a) is a soluble IL-BKW lacking the sequence MNFQQRLQSL WTLARPFCPP LLATASQMOM VVLPCLGFTL LLWSQVSG of SEQ ID NO: 2;
  - 15 b) is a mature polypeptide of SEQ ID NO: 6; or
  - c) is encoded by a nucleic acid of SEQ ID NO: 5.
- 20 5. The IL-BKW of claim 2, which is a full length secreted protein which exhibits a post-translational modification pattern distinct from natural IL-BKW.
- 25 6. The IL-BKW of claim 2, which exhibits an antagonist immunological activity of IL-10.
7. A fusion protein comprising sequence of a protein or peptide of claim 2, wherein said protein or peptide:
  - a) lacks a sequence of MNFQQRLQSL WTLARPFCPP LLATASQMOM VVLPCLGFTL LLWSQVSG of SEQ ID NO: 2;
  - 30 b) is a mature polypeptide of SEQ ID NO: 6; or
  - c) is encoded by a nucleic acid of SEQ ID NO: 5.
- 35 8. A sterile composition comprising a protein or peptide of claim 2.

9. A method of purifying an IL-BKW protein or peptide of claim 6 from other materials in a mixture comprising contacting said mixture to an antibody to said protein, and separating bound IL-BKW from other materials.

5

10. An isolated or recombinant expression vector encoding a soluble IL-BKW of claim 1.

11. The vector of claim 10, wherein said nucleic acid 10 encodes a secreted sequence of SEQ ID NO: 2 or 6

12. The vector of claim 10, which comprises a sequence of SEQ ID NO: 1 or 5.

15 13. A kit for detection comprising a positive control which is a substantially pure soluble IL-BKW or fragment of claim 1.

20 14. A method for detecting in a sample for the presence of an IL-BKW nucleic acid, protein, or antibody, comprising testing said sample with a kit of claim 11.

25 15. A method of modulating the physiology of a cell comprising contacting said cell with a substantially pure soluble IL-BKW of claim 1.

16. The method of claim 15, wherein said cell is a T cell and said modulating of physiology is inactivation of said T cell.

30

17. The method of claim 15, wherein said cell is in a tissue.

35 18. A method of making a soluble IL-BKW comprising expressing a vector of claim 10.

19. A cell, tissue, or organ comprising a vector of claim 10.
20. A method of treating a mammal having an abnormal immune response by administering to said mammal an effective dose of a substantially pure soluble IL-BKW.  
5

1/1

HELI<sub>A</sub>  
HELI<sub>B</sub>

 $\alpha_1$ 

vIL10	...TDQC...	DNFPQMIRDLRDAFSRVRKTFOTKDEV
Mol10	SRGQYSREDDNNCTHFPVGQSHMLLIELRTAFSQVKITFFOTKDEV	DNLKESSELDFKGYLGCGAISEMIQFYLEEVWMPQABNQDPE...
HuIL10	SPGQGTQSENNSCTHFPGNLPNMLRDILRDAFSRVRKTFQMDQL...	DNLKESSELDFKGYLGCGAISEMIQFYLEEVWMPQABNQDPE...
HuAK155	KHKQSSFTKSC.YPRGTLSQAVDALYIKAALWLKATIPEDRIK.	DNLKESSELDFKGYLGCGAISEMIQFYLEEVWMPQABNQDPE...
HuIL19	...LRRAC...	NIRLLKKTKKKQEM.NIRLLKKTKKKQEM.
HuIL20	AQGQEFHFGPC.QVKG...	EESEFQEIKRAICAKDTFPNVITLSTLEI[QI]KPDVCCVTKNLAFFVDRVFRDHQEPNPK...
Mol120	LEGQEFRSSGSC.QVTG...	DNLKESSELDFKGYLGCGAISEMIQFYLEEVWMPQABNQDPE...

 $\alpha_2\text{-}C4$ 

C1-C8

vIL10	AKDHVNSLGENLKTTLRLRIRRCHRFLPCENK...	SKAVEQIKNAFENKLQ...	EKGIVYKAMSEFDIFINY[EAYMTIKAR]
Mol10	KEHLNLSGEKLKTLMRMRRCHRFLPCENK...	SKAVEQVKSDFNKLQ...	DQGVVKAMSEFDIFINY[EAYMTIKAR]
HuIL10	KAHVNSLGENLKTTLRLRIRRCHRFLPCENK...	SKAVEQVKNAFNKLQ...	EKGIVYKAMSEFDIFINY[EAYMTIKAR]
HuAK155	CKKIREVIEDFATLHQKLISHCIS...	CASSAREMKSTITRKWKRIFYRIG...	NKGIVYKAISELIDLISWKKLLESSQ...
HuIL19	[LRK]ISSANSFLYV[QKTT]RQC...	[IHDNYDQLEVHAAA]KSLGELDVFL...	AWI[NKNHEVMSA]
HuIL20	TLKSFSTANNFVLIVSQLOPS...	QENEMFSIRD[SAHARF]FQLDVEAALT...	TW[QXFYKL]...
Mol120	VLRSFSTANNFVLIVSQLOPS...	KDNSMLPISESAHQRELL...	TW[QXFYHL]...

## HELIX C

 $\alpha_2$ 

*Structure based alignment of IL10 & closely related cytokines*

## HELIX D

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 97/22975

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/19 C07K14/54 C12N15/62 G01N33/50 C12Q1/68 A61K38/19 C12N5/10 A01K67/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C12N C07K G01N C12Q A61K A01K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JIANG H ET AL: "Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression" ONCOGENE, vol. 11, 1995, pages 2477-2486, XP002064717 cited in the application see page 2484, right-hand column, last paragraph - page 2485; figure 1	1-6, 8-14,18, 19
X	WO 95 11986 A (UNIV COLUMBIA) 4 May 1995  see page 223 - page 228; figure 38 see page 324 - page 329	1-6, 8-14,18, 19

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

13 May 1998

Date of mailing of the international search report

20.05.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patenttaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Espen, J

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US 97/22975

**Box I Observation where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
  
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

See continuation-sheet

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-3,5,6,8-10,13,15-20; in part 4,7,11,12,14

IL-BKW protein, fusion protein comprising a sequence of IL-BKW protein, method of purifying an IL-BKW protein, vector encoding an IL-BKW protein, kit for detection, method for detection, method of modulating the physiology of a cell; cell,tissue, or organ comprising vector encoding an IL-BKW protein

2. Claims: in part: 4,7,1,12,14

IL-BKW protein lacking the sequence of amino acid residues 1-48 of SEQ ID NO 2, fusion protein comprising said protein, vector encoding said protein, method for detection

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/22975

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9511986	A 04-05-1995	US 5643761 A		01-07-1997
		AU 8088394 A		22-05-1995
		EP 0730659 A		11-09-1996
		JP 9507021 T		15-07-1997